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The T-box gene family has achieved great prominence in the field of developmental biology 
because its members have been demonstrated to play important roles in embryonic development 
and mutations within several T-box genes are associated with a number of human congenital 
diseases. Several lines of evidence have also implicated members of the T-box gene family in 
cell cycle regulation and in cancer. Importantly, the highly related T-box factors, Tbx2 and Tbx3, 
can suppress senescence through repressing the cyclin dependent kinase inhibitors, p21wAF11 
c1P118011 and p19ARF. Both Tbx2 and Tbx3 have also been linked to several cancers primarily 
because their expression levels have been found to be deregulated in these cancers. However, 
despite the pivotal role that members of the T-box family play in a wide variety of biological 
processes, very little is known about the biochemical pathways that regulate their levels and 
transcriptional activity. In view of the detrimental consequences resulting from altered levels of 
T-box proteins, as seen both in developmental disorders and in certain cancers, the need to 
identify such pathways is important. The aim of this study was therefore to identify kinases that 
phosphorylate and regulate the levels and activity of Tbx2 with the view to understanding its 
role in cell cycle regulation and cancer. This study shows that the p38 stress mitogen-activated 
protein kinase, and the mitotic cyclin A/Cdk2 and cyclin B1/Cdk1, are direct regulators of Tbx2 
both in vitro and in vivo. 
It is possible that Tbx2 and Tbx3 may contribute towards the oncogenic process through 
their anti-senescence function, especially since a dominant negative form of Tbx2 induces 
senescence in melanoma cells overexpressing Tbx2. However, very little is known about 
whether Tbx2 is indeed regulated during replicative- or stress-induced senescence. In this 
study, using a breast cancer cell line known to overexpress Tbx2, the Tbx2 protein is shown to 
be specifically phosphorylated by the p38 kinase in response to stress induced by ultraviolet 
irradiation. Using site-directed mutagenesis and in vitro kinase assays, serine residues 336, 
623 and 675 in the Tbx2 protein were identified as p38 target sites. These sites are also shown 
to be phosphorylated in vivo. Importantly, western blotting, immunofluorescence and reporter 
assays reveal that this phosphorylation leads to increased Tbx2 protein levels, predominant 
nuclear localisation of the protein, and an increase in the ability of Tbx2 to repress the p21wAF11 
c/P118011 promoter. These results show, for the first time, that the ability of Tbx2 to repress the p21 
gene is enhanced in response to a stress-induced senescence pathway. This leads to a better 
understanding of the anti-senescence function of Tbx2. 
viii 
The ability of Tbx2 to function as an anti-senescence factor, as well as its altered regulation 
being associated with certain cancers, suggests that"its levels may need to be tightly regulated 
during the cell cycle. Indeed, the Tbx2 protein was previously shown to be regulated during the 
various phases of the cell cycle, peaking at G2. The changes in the Tbx2 protein levels did not 
match changes in Tbx2 mRNA levels, suggesting that the protein may be regulated by post-
translational modifications such as phosphorylation. This study shows that the phosphorylation 
status of Tbx2 is regulated during the cell cycle with levels of phosphorylation peaking in G2 
and M, in mouse and human cells respectively. Phosphorylation was shown to be specifically 
mediated by the mitotic kinases as demonstrated in experiments when the mitotic kinase inhibitor, 
olomoucine, was included. This study provides data to suggest that Tbx2 may be regulated 
differently during the cell cycle in mouse and human cells. Using site-directed mutagenesis 
and in vitro kinase assays, Tbx2 was found to be specifically phosphorylated at serine residues 
192 and 336 by cyclin A/Cdk2 and serine residues 336 and 342 by cyclin 81/Cdk1. These sites 
are also targets for phosphorylation in vivo since mutating them altered the phosphorylation 
status ofTbx2. Moreover, both cyclin A and 81 were shown to bind Tbx2 in vitro and in vivo and 
the minimal region required for binding was mapped to its DNA-binding domain. Importantly, 
immunofluorescence demonstrates that the Tbx2 protein localises specifically to the nucleus at 
G2; this translocation was shown to be blocked in the presence of olomoucine. Furthermore, 
western blot analyses and reporter assays showed that pseudo-phosphorylation by cyclin 81/ 
Cdk1, but not cyclin A/Cdk2, leads to increased Tbx2 protein levels and an increase in the 
ability of Tbx2 to repress the p21wAFtiCIPt!Sou promoter. These results disclose, for the first time, 
that phosphorylation by cyclin A/Cdk2 and cyclin 81/Cdk1 of the Tbx2 protein regulates its 
activity. This data provide additional evidence to support a role for Tbx2 in the G2 and/or M 
phase of the cell cycle. 
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CHAPTER 1: INTRODUCTION AND AIMS 
1.1 Introduction 
The T-box gene family encodes transcription factors that are defined by the conservation of 
the DNA-binding domain known as the T-box (Kispert and Herrmann, 1993; Bollag et al., 1994; 
Agulnik et al., 1995; reviewed in Papaioannou, 2001). This family plays an important role in. 
embryonic development such as the specification of primary germ layers and cell fates during 
organogenesis (reviewed in Showell et al., 2004). Consistent with this role, mutations within 
several T-box genes are associated with a number of human congenital diseases. Recently, 
the T-box family members, Tbx2 and the very closely related factor, Tbx3 have also been 
implicated in cell cycle regulation and cancer. For example, their expression is upregulated 
in a number of cancers, including breast (Sinclair et al., 2002; Fan et al., 2004), pancreatic 
(Mahlamaki et al., 2002; Hansel et al., 2004), melanoma (Vance et al., 2005; Hoek et al., 
2004), liver (Renard et al., 2007) and bladder (Ito et al., 2005). Both Tbx2 and Tbx3 function 
as transcriptional repressors (Carreira et al., 1998; Carlson et al., 2001; He et al., 1999; Sinha 
et al., 2000), and have been shown to prevent senescence through a mechanism involving 
their ability to repress the cyclin dependent kinase inhibitors pHJARF (Jacobs et al., 2000; 
Brummelkamp et al., 2002; Lingbeek et al., 2002) and p21wAF11c1P115011 (referred to as p21) 
(Prince et al., 2004; Vance et al., 2005). Tbx3 can also cooperate with oncogenic Myc and 
Ras to induce cellular transformation and suppress apoptosis through repression of p19ARF 
expression and p53 protein levels (Carlson et al., 2002). 
Even though members of the T-box family have been shown to play a pivotal role in a wide 
variety of developmental processes and to be implicated in tumourigenesis, very little is known · 
about the biochemical pathways regulating the expression and activity of these transcription 
factors. Furthermore, while several studies have defined them as transcription activators and 
repressors there is a paucity of information regarding their target genes (reviewed in Naiche 
et al., 2005). The recent discovery of the involvement ofT-box proteins in the cell cycle and 
cancer has intensified the need to elucidate their precise role in the regulation of these cellular 
processes. 
This review will provide a general overview of the current literature on the regulation of Tbx2 
during development, the cell cycle and cancer, and to introduce key areas of research pertaining 
to this thesis. 
1.2 The T-box family 
The T-box gene family is an ancient gene family as indicated by phylogenetic analysis. It is 
thought to have initally arisen in the common ancestor of metazoan organisms and that a 
genome wide duplication occurred over 600 million years ago in the early evolution of vertebrates 
(Agulnik et al., 1996). Following deviation from the common ancestor, further divergence by 
gene duplication occurred along individual evolutionary lineages: current phylogenetic analyses 
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have divided the family into five subfamilies, namely T, Tbx1, Tbx2, Tbx6 and Tbr1 (reviewed 
in Papaioannou and Silver, 1998). To date, 17 mammalian T-box genes have been identified 
(reviewed in Naiche et al., 2005). These genes are highly conserved in evolution with family 
members found in a wide range of organisms, including nematodes, frog, chick, mouse and 
human (reviewed in Papaioannou, 2001; Papaioannou and Silver, 1998 and Smith, 1999). The 
T-box comprises a region of approximately 200 amino acid residues, which can be located 
anywhere within the protein (reviewed in Smith, 1999) and specific residues within this region 
are highly conserved in all members of the family (reviewed in Wilson and Conlon, 2002). The 
T-box region does not possess sequence similarity to any known DNA-binding motif of other 
transcription factors (reviewed in Wilson and Conlon, 2002). 
The prototype of the T-box family, Brachyury or T, is by far the most extensively studied and 
has been utilised as a model for elucidating the structure and function of other family members. 
The N-terminal half of the T protein contains the T-box responsible for binding to DNA, whereas 
the C-terminal region is required for transcriptional activation (Kispert and Herrmann, 1993; 
Kispert et al., 1995; Conlon et al., 1996). Brachyury binds to the 24 bp palindromic sequence 
AATTT(G/C)ACACCTAGGTGTGAAATT (Kispert and Herrmann, 1993; Muller and Herrmann, 
1997) and in vitro studies have shown that it can bind as a monomer to a variety of differently 
spaced and orientated half sites, such as AGGTGTGAAATT, within this palindrome (Kispert 
et al., 1995; Conlon et al., 2001; reviewed in Papaioannou, 2001). In the past decade several 
family members have been identified in a variety of organisms and all members tested to date 
also recognise the above palindromic response element (reviewed in Naiche et al., 2005). The 
target specificity of T-box proteins is thought to depend on accessory proteins as well as the 
difference in spacing and orientation of half sites within the palindrome (Kispert et al., 1995; 
Conlon et al., 2001; Sinha et al., 2000; reviewed in Papaioannou, 2001 ). 
T-box proteins can function as either transcriptional activators or repressors (Kispert et al., 
1995; Conlon et al., 1996; Carreira et al., 1998; Stannard ·et al., 2003) with some T-box 
factors, such as Tbx20a (Tbx20 isoform) (Stannard et al., 2003) and Tbx2 (Paxton et al., 2002) 
possessing both activation and repression domains. Indeed, in vitro studies have revealed 
that Tbx20a and Tbx2 can act as either activator or repressor, depending on the cell context. 
Their role as transcriptional regulators is well documented but very little is known about the 
mechanism(s) by which T-box factors execute their function and how they themselves are 
regulated. It is however anticipated that the function ofT-box proteins are regulated by protein-
protein interactions with other transcription regulators and recent studies have revealed the 
importance of co-activators in the function of certain T-box proteins. Murakami et al. (2005) 
have identified the WW-domain-containing transcription regulator, TAZ (Kanai et al., 2000) as a 
potent co-activator of TBX5·. In this study the investigators show that TAZ physically associates 
with TBX5 and histone acetyltransferase (HAT) proteins to mediate TBX5-dependent gene 
activation. 
• The accepted convention will be used for human (TBX2) and when referring to both human and 
mouse, TBX2/Tbx2 will be used. 
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In another study, Tpit (Tbx19) was shown to drive expression of the pro-opiomelanocortin 
(POMC) gene in pituitary cells by recruiting the co-activators SRC/p160 and then co-
operating with the homeoprotein, Pitx1 (Lamolet et al., 2001; Maira et al., 2003). 
While it is evident that the specificity of T-box factors for their target genes are due 
to variations between T-elements and differences in their regulatory domains, the answer as 
to how these transcription factors can possess such diverse roles in different cell/tissue types 
lies in the identification of accessory proteins constituting the transcriptional machinery needed 
for their activity. 
Since T-box proteins are DNA-binding transcription factors, their localisation to the nucleus is 
essential in order to regulate their target genes. It is therefore anticipated that their subcellular 
distribution plays an important role in the regulation of their activity. Indeed, Tbx5 localises to 
both the nucleus and cytoplasm in tissue sections from developing chick hearts (Bimber et 
al., 2007), which suggests that its nuclear localisation is regulated. Importantly, in DiGeorge 
syndrome patients, the 1223deiC mutation within Tbx1 not only prevents nuclear localisation 
but also abolishes the transcription activation property of the protein (Stoller and Epstein, 
2005). In this study, when the 1223deiC Tbx1 mutant was forced to localise to the nucleus 
by fusing the protein to the SV40 nuclear localisation signal (NLS), Tbx1 was still unable to 
activate transcription of a luciferase reporter vector, indicating the need of the mutated region 
for its transactivational activity. This study may provide an explanation for the haploinsufficiency 
of the TBX1 protein in patients with DiGeorge syndrome. 
Nuclear localisation signals have been identified in several members of the T-box family 
including Tbx1 (Stoller and Epstein, 2005), Tbx3 (Carlson et al., 2001 ), TBX5 (Zaragoza et al., 
2004), Tbx6 (Uchiyama et al., 2001) and Veg T (Zhang and King, 1996), and have been shown 
to play an important role in their nuclear localisation. For example, deletion of the TBX5 NLS, at 
amino acids 325-327 within its C-terminal region, is sufficient to prevent nuclear localisation of 
the protein (Zaragoza et al., 2004 ). The NLS in Tbx1 is also conserved in Brachyury and Tbx1 0 
of mouse and human, and is sufficient to localise these transcription factors to the nucleus 
when expressed as GFP/j3-GAL fusion proteins (Stoller and Epstein, 2005). It is important 
to note that NLS domains have not yet been identified for several T-box factors. This might 
suggest that these T-box proteins have novel NLS sequences or that they require binding to a 
NLS-containing protein(s) to chaperone them to the nucleus. 
The T-box family has achieved great prominence in the field of developmental biology. Since 
the discovery of the first T-9ox factor, several studies have focused on the cloning of other 
family members and the determination of their spatial and temporal expression patterns during 
development. T-box factors are expressed throughout development where their function 
ranges from the specification of primary germ layers to the determination of cell fate during 
organogenesis (reviewed in Showell et al., 2004). Indeed, the importance of this gene family in 
development is underscored by the fact that mutations in several T-box genes are associated 
with a number of developmental defects (Table 1.1 ). In humans, a number of autosomal 
dominant and semi-dominant genetic syndromes have been linked to mutations in the T-box 
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Table 1.1. The phenotypic effects of known mutations in the, mouse and human T-box genes 
(Adapted from Naiche et al., 2005). 
I 
Mouse gene; human Human syndrome Mouse heterozygote Mouse homozygote 
gene phenotype phenotype 
I 
T; T Not known Short tail Embryonic lethal, inhibits 
mesoderm induction 
Tbx19; TBX19 (TPIT) Recessive isolated Normal ACTH deficiency, pigment 
ACTH deficiency defects 
Tbx1; TBX1 DiGeorge, craniofacial , Viable, thymus and Neonatal lethal ; 
glandular, vascular and vascular abnormalities craniofacial , glandu lar, 
heart abnormalities vascular, and heart 
abnormal it ies 
Tbx10; TBX10 Not known Susceptibility to cleft Cleft lip and palate 
lip and palate (Dancer: (Dancer: ectopic-gain-of-
ectopic-gain-of-function) function) 
Tbx15; TBX15 Not known Normal Craniofacial viable, 
malformations and 
p igment pattern 
alterations (droopy ear) 
Tbx18; TBX18 Not known Normal Postnatal lethal, vertebral 
malformations 
Tbx20; TBX20 Not known Heart contractile function Embryonic lethal, heart 
defects abnormalities 
Tbx22; TBX22 X-linked cleft palate with Not known Not known 
ankyloglossia 
Tbx2; TBX2 Not known Normal Embryonic lethal, heart 
and limb abnormalities 
Tbx3; TBX3 Ulnar-mammary: Hypoplastic mammary Embryonic lethal, yolk 
hypoplastic mammary glands, abnormal external sac, limb and mammary 
glands, abnormal genitalia gland defects 
external genitalia, limb 
abnormalities 
Tbx4; TBX4 Small patella Reduced allantois growth Embryonic lethal, 
rate allantois and hindlimb 
defects 
Tbx5; TBX5 Holt-Oram, heart and Heart abnormalities, Embryonic lethal, severe 
hand abnormalities reduced viability heart malformations 
Tbx6; TBX6 Not known Normal Embryonic lethal, somite 
abnormalities 
Tbr1; TBR1 Not known Normal Olfactory bulb and 
cortical defects 
Eomes; EOMES Not known Normal Embryonic lethal, 
trophoblast and 
mesoderm failure 
Tbx21; TBX21 (TBET) Not known Airway Airway 
hyperresponsiveness, hyperresponsiveness, no 
intermediate INF-y levels Th1 cells 
in Th1 cells 
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genes. For example, mutations in TBX3 are linked to the-autosomal dominant ulnar-mammary 
syndrome (Bamshad et al., 1997), while TBX22 mutations are associated with the semi-
dominant X-linked disorder, cleft palate with ankyloglossia (Braybrook et al., 2001 ). Dosage 
sensitivity or haploinsufficiency is postulated to be the mechanism by which mutations in T-box 
genes are responsible for these developmental defects. 
Very little is known about the signalling pathways that regulate the expression ofT-box factors 
during embryonic development and even less is known about the complex regulation of the 
expression profiles of T-box genes post-embryogenesis. Over the last few years there has 
therefore been a shift towards elucidating the regulation and function of T-box proteins at a 
molecular level. One approach has been to identify the signalling pathways that regulate T-box 
factors and another has been to determine their target genes. Members of the transforming 
growth factor-(3 (TGF(3), fibroblast growth factor (FGF) and Wnt signalling pathways are key 
players in the regulation of cellular proliferation, differentiation and patterning during early 
embryonic development and have been shown to both be regulators of, and to be regulated by, 
certain T-box genes (reviewed in Shi and Massague, 2003; Thisse and Thisse, 2005; Logan 
and Nusse, 2004 and Showell et al., 2004). Due to the multiple roles ofT-box factors during 
development, the following discussion will focus on Tbx2 and, where appropriate, the role of 
other family members. 
1.3 Tbx2 
Tbx2 belongs to the Tbx2 subfamily ofT-box transcription factors which include Tbx3, Tbx4 and 
Tbx5 (Bollag et al., 1994; Agulnik et al., 1996). TBX2 is most closely related to TBX3 (12q24.1 ), 
whereas TBX4 and TBX5 are more closely related to one another. During development, Tbx2 
has been implicated in several processes, such as coordinating the cell fate, patterning and 
morphogenesis of a wide range of tissues and organs including limbs, kidneys, lungs, mammary 
glands, heart and craniofacial structures. Furthermore, Tbx2 and the family member Tbx3 are 
also emerging as key regulators of the cell cycle and dosage sensitivity of these two T-box 
genes have been implicated in several cancers. 
1.3.1 Tbx2 gene and protein 
In mouse Tbx2 is located within chromosome 11 (Bollag et al., 1994) and in humans, TBX2 has 
been mapped to chromosome 17q23 (Campbell et al., 1995). The T-box region of the human 
TBX2 transcription factor shares 90% DNA sequence homology and 96% peptide sequence 
homology with its mouse counterpart (Law et al., 1995). Both human and mouse Tbx2, which 
span 3.378 kb and 2.281 kb respectively, possess 7 exons (Fig. 1.1). In mouse, Tbx2 is 
expressed in adult heart, lung, kidney, ovary and in cells of the melanocyte lineage (Bollag 
et al., 1994; Carreira et al., 1998). TBX2 is expressed in a wide variety of tissues including 
fetal kidney and lung as well as in a number of adult tissues such as kidney, lung, placenta, 
ovary, prostate, spleen, testis, breast, heart, thymus, intestine and polymorphonucleocytes 
(Law et al., 1995; Campbell et al., 1995). While loss or altered expression of Tbx2 has not 
been associated with any developmental syndrome, mutational studies in mice have shown 




1 (676 bp) 2 (268 bp) 3 (147 bp) 4 (77 bp) 6 (635 bp) 7 (1 411 bp) 
5'UTR 
5 (164 bp) 3' UTR 
Human TBX2 mRNA (3.378 kb) 
1 (424 bp) 2 (268 bp) 3 (147 bp) 4 (77 bp) 6 (638 bp) 7 (563 bp) 
5' UTR 5 (164 bp) 
Mouse Tbx2 mRNA (2.281 kb) 
- Exon - - lntron c=.J Untranslated region (UTA) 
Human : Tbox 
Mouse : Tbox 
104 - 285 
114 - 295 
1 MAYHPFHAPRPADFPMSAFLAAAQPSFFPALALPPGALAK PLPDPGLAGA 
1 MREPALAASAMAYHPFHAPRPADFPMSAFLAAAQPSFFPALALPPGALGKPLPDPGLAGA 
5 1 AAAAAAAAAAAEAGLHVSALGPHPPAAHLRSLKSLEPEDEVEDDPKVTLEAKELWDQFHK 
61 AAAAAAAAAAAEAGLHVSALGPHPPAAHLRSLKSLEPEDEVEDDPKVTLEAKE LWDQFHK 
111 LGTEMVITKSGRRMFPPFKVRVSGLDKKAKYILLMDIVAADDCRYKFHNSRWMVAGKADP 
121 LGTEMVITKSGRRMFPPFKVRVSGLDKKAKYILLMDIVAADDCRYKFHNSRWMVAGKADP 






351 DPEPERLSEE RAGAPLGRSPAP DSASPTRLTEPE RARERRSPERG KEPAESGGDGPFGLR 
361 DPEPERTGEERSAAPLGRSPSRD ASPARLTEPERSRERRSPERCSKEPTEGGGDGPFSLR 
411 SLEKERAEARRKDEGRKEAAEGKEQGLAPLVVQTDSASPLGAGHLPGLAFSSHLHGQQFF 
421 SLEKERPEARRKDEGRKDVGEGKEPSLAPLVVQTDSASPLGAGHLPGLAFSSHLHGQQFF 




590 AAAAGSLSRSPFLGSARPRLRFSPYQIPVTIPPSTSLLTTGLASEGS KAAGGNSREPSPLPE 
601 AAAAGSLSRSPFLGSARPRLRFSPYQIPVTIPPSTSLLTTGLAAEGSK GGNSREPSPLPE 
652 LALRKVGAPSRGALSPSGSAKEAANELQSIQRLVSGLESQRALSPGRESPK (702) 
66 1 LALRKVGGPSRGALSPSGSAKEAASELQSIQRLVSGLESQRALSPGRESPK (711) 
3' UTR 
Figure 1.1. Comparative analysis of the Tbx2 gene and protein between human 
(a) Schematic representation of the human and mouse Tbx2 gene 
relative positions and sizes of the 7 exons. (b) Alignment of 
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of severe cardiac defects (Harrelson et al., 2004). This result suggests a crucial role for Tbx2 
during cardiac development. 
In human the TBX2 protein consists of 702 amino acids with the T-box DNA-binding domain 
located at amino acids 1 04-285, whereas in mouse the T-box is located at amino acids 114-
295 within the 711 amino acid protein (Fig. 1.1 ). Due to the high degree of homology between 
the DNA-binding domain of Brachyury and Tbx2, investigators have utilised Brachyury as a 
model to gain insight into the DNA-binding specificity of Tbx2. These studies show that Tbx2 
binds as a monomer to the Brachyury single half-sites, recognising the consensus sequences 
GTGTGA, GGGTGA or GTGTTA (Carreira et al., 1998). Furthermore, TBX2 binds both the 
Brachyury palindromic and half sites equally well (Sinha et al., 2000). Mutating an arginine 
at position 122, which is conserved in all T-box factors, abolished the DNA-binding activity of 
TBX2 in vitro without affecting its stability and nuclear localisation (Sinha et al., 2000). 
Unlike most members of the T-box family that function as transcription activators, Tbx2 is a 
potent repressor of its target genes (Carreira et al., 1998; He et al., 1999; Sinha etal., 2000). 
Using different Tbx2 deletion constructs linked to a CAT reporter gene containing a single T-
element binding site, Paxton et al. (2002) was able to map the regulatory domains within the 
mouse Tbx2 protein. They identified two separate transcription repression domains; a novel 
amino-terminal repression domain (between amino acids 1-53) and confirmed the presence of 
a carboxy-terminal (between amino acids 529-573) repression domain identified in an earlier 
study (He et al., 1999; Paxton et al., 2002). A weak activation domain was also located within 
the T-box and depending on the promoter context; Tbx2 was capable of also activating gene 
expression (Paxton et al., 2002). Deletion of the carboxy-terminal repression domain only 
minimally reduces the ability of Tbx2 to repress gene expression, whereas deletion of both 
repression domains abolishes the repressor activity of Tbx2 (Paxton et al., 2002). This would 
suggest that the repression domain located in the amino-terminus is important in mediating 
the ability of Tbx2 to repress its target genes. The presence of both activation and repression 
domains within the Tbx2 protein suggests multiple but specific roles for this transcription factor 
depending on the cellular context or species. Indeed, in an attempt to identify genes that may 
be regulated by Tbx2, eDNA microarray analysis was performed on mouse NIH 3T3 fibroblasts 
overexpressing Tbx2 and the results revealed that the type 1 collagen gene was upregulated 
(Chen et al., 2001 ). Interestingly, a parallel investigation in which Tbx2 was overexpressed in 
the rat ROS17/2.8 osteoblastic cell line showed down-regulation of type I collagen (Chen et 
al., 2001 ). These contrasting results suggest that the cell context and/or the species may be 
important in determining the effect of Tbx2 on the expression of the type I collagen genes. 
1,3.2 Role of Tbx2 in embryonic development 
Heart Development 
During cardiogenesis, Tbx2 is required for proliferation and patterning of the developing heart 
(Harrelson et al., 2004). The vertebrate heart originates from a linear tube that undergoes a 
series of complex looping and partitioning to form the multi-chambered organ. At the onset 
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of looping, the heart tube is compartmentalised into chamber myocardium, which form the 
atria and the ventricles, and non-chamber myocardium, which forms the outflow tract, the 
atrioventricular canal, the inflow tract and the inner curvatures. Together the chamber and non-
chamber myocardium form the cardiac conduction system, which essentially controls the heart 
rate (reviewed in Christoffels et al., 2004). At around 8 and 10 days post coitus (dpc), Tbx2 is 
detected in the non-chamber myocardium of the developing mouse heart (Fig. 1.2) {Christoffels 
et al., 2004; Habets et al., 2002). This is consistent with Tbx2 expression patterns in chick 
heart development (Gibson-Brown et al., 1998; Yamada et al., 2000). Tbx3 is co-expressed 
with Tbx2 in the heart and it is postulated to function redundantly with Tbx2 in regulating 
target gene expression {Christoffels et al., 2004; Hoogars et al., 2004; Lingbeek et al., 2002). 
Bone morphogenic proteins (BMPs) belong to the TGF-13 family of signalling transducers and 
are important in the development of the non-chamber myocardium (reviewed in Delot, 2003). 
There is accumulating evidence that Tbx2 and Tbx3 may be downstream Bmp2 targets during 
heart development. Firstly, the expression patterns of Tbx2 and Tbx3 overlap significantly with 
bmp2 during chick heart development (Yamada et al., 2000). Secondly, ectopic expression of 
Bmp2 was shown to induce Tbx2 and, to a lesser extent, Tbx3 expression in non-cardiogenic 
tissue that is competent to form cardiac tissue. Moreover, in the same study when chick cardiac 
tissue explants were incubated with Noggin, a panantagonist of BMP signalling, Tbx2 was 
downregulated with only very little effect on Tbx3. Furthermore, mouse bmp2"'· embryos show 
marked morphological abnormality in cardiac development {Zhang and Bradley, 1996) and 
Tbx2 gene activity is substantially reduced in the cardiac region of these embryos (Yamada et 
al., 2000). Tbx20, which is required for the proliferation of myocardium (Cai et al., 2005), was 
also shown to be down regulated together with Tbx2 and Tbx3 in the developing hearts of Bmp 
mice in which the type 1 Bmp receptor was ablated (Yang et al., 2006). These studies indicate 
that the BMP pathway is an important upstream modulator of T-box gene expression during 
heart development. 
Recent studies have identified Tbx2 target genes which have shed light on its functional role 
during early heart development. The formation of the chamber and non-chamber myocardium 
requires a distinct gene expression profile, and a number of chamber and non-chamber specific 
genes have been characterised. For example, expression of natriuretic precursor peptide type 
A (Nppa), connexin (Cx) 40, Cx43 and atrial natriuretic factor (ANF) are important for the 
differentiation and formation of the chamber myocardium (Christoffels et al., 2000; Christoffels 
et al., 2004). Formation of the non-chamber myocardium on the other hand requires the 
expression of a different set of genes which involves Tbx2 (Christoffels et al., 2004; Habets et 
al., 2002). Tbx2 normally inhibits cell proliferation and chamber differentiation in non-chamber 
myocardium, and it is thought that chamber differentiation requires its repression by Tbx20 
(Cai et al., 2005). Tbx20, a positive regulator of chamber formation, binds and transcriptionally 
represses Tbx2 via aT-element (Cai et al., 2005). Given the ability of Tbx2 to repress Nmyc1, 
which is required for the normal proliferation of the heart (Davis and Bradley, 1993), it is 
proposed that in chamber myocardium Tbx20 represses Tbx2 thus preventing its repression of 
Nmyc1 (Cai et al., 2005). However, in non-chamber myocardium repression of Tbx2 by Tbx20 is 
abolished, allowing Tbx2 to repress Nmyc1 and the early cardiac genes, resulting in decreased 
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Figure 1.2. The role of Tbx2, Tbx3, Tbx5 and Tbx20 in early heart development. Schematic 
representation of an E9.5-10.5 chamber forming heart showing T-box patterning in the different 
emerging structures. Tbx2 and Tbx3 exert their function in the non-chamber myocardium, Yellow 
bars indicate expression patterns of Tbx5 and Tbx20. Tbx5 is required for anterior-posterior 
patterning and, along with Tbx20, for chamber differentiation. The primary myocardium is in 
gray, the ventricular myocardium is in red, and the atrial myocardium is in blue. A, anterior; at, 
atrium; ave, atrioventricular canal; D, dorsal; ift, inflow tract; lv, left ventricle; oft, outflow tract; 
P, posterior; rv, right ventricle; V, ventral. (Modified from Christoffels et al., 2004 and Hoogaars 
et al., 2007). 
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proliferation within this region (Cai et al., 2005; Stennard et al., 2005). In vitro reporter assays 
and transgenic mice studies have shown that during non-chamber formation, Tbx2 represses 
the transcription of Nppa, Cx40, Cx43 and ANF and thus plays a role regulating the formation 
of the multi-chambered heart (Christoffels et al., 2004; Habets et al., 2002). 
During heart development the non-chamber myocardium retains the embryonic myocardial 
phenotype of the tubular heart longer than the chamber myocardium. The ANF gene is 
specifically expressed in the developing chamber myocardium and is one of the first hallmarks 
of chamber formation (Christoffels et al., 2000), which raises the question of how this gene 
is repressed in the non-chamber myocardium. This was addressed by studies which found 
that mutating two adjacent binding sites forT-box factors and Nkx2.5, respectively, abrogated 
repression of ANF in regions of the non-chamber myocardium (Habets et al., 2002). 
Furthermore, whereas Tbx2 and Tbx3 were shown to co-operate with Nkx2.5 to suppress ANF 
promoter activity in embryonic myocardium (Habets et al., 2002; Hoogaars et al., 2004), Tbx5 
conversely bound the same site and co-operated with Nkx2.5 to activate ANF gene expression 
in chamber myocardium (Bruneau et al., 2001; Hirai et al., 2001 ). Together, these findings point 
to a complicated network in which several T-box factors act in the patterning, proliferation and 
morphogenesis of the developing heart. 
Brain Development 
The hypothalamus is situated in the area of the brain just below the thalamus and is important 
in regulating body temperature, blood pressure, weight regulation, and many other autonomic-
nervous system activities such as fear, rage and sexual behaviors (van de Graaff, 2002). Both 
in vitro and in vivo studies have implicated Tbx2 in the patterning and development of the 
hypothalamus. Much of the evidence for this results from work done in chick on a subset of 
hypothalamic cells, termed the ventral tubero-mamillary (vt-m) cells which arise from a set of 
floor plate-like precursors (Manning et al., 2006). The floor plate-like precursors initially express 
Sonic hedgehog (Shh) but require its downregulation in order to progress to vt-m cells. BMPs 
have previously been shown to down regulate Shh in a wide variety of tissues and Manning et 
al. (2006) show that down regulation of Shh in the vt-m cells occurs by a BMP-Tbx2 signalling 
pathway. Both overexpression and knock-down experiments showed that Tbx2 downregulates 
Shh in the vt-m hypothalamus. Furthermore, Jeong and Epstein (2003) identified a T-element 
in the mouse Shh promoter and they show that mutating this T-element result in aberrant 
expression of Shh within the hypothalamus. In Manning et al. (2006), BMPs were shown to 
upregulate Tbx2, which may involve the ability of BMPs to antagonise Wnt. In the presence of 
the BMP inhibitor, chord in, expression of Tbx2 was downregulated in the vt-m hypothalamus. 
In contrast, blocking BMP and Wnt signalling was shown to rescue the expression of Tbx2 in 
the vt-m cells. The results by Manning et al. (2006) raise the possibility that the T-element in 
Shh is regulated by Tbx2 in the hypothalamus. 
Eye Development 
Expression of Tbx2 and other members of the T-box family may be important for the growth and 
patterning of the mammalian embryonic eye. In the mouse embryo, eye development begins 
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at embryonic day 8.5 and involves the formation of a bilayered optic cup which gives rise to 
the neural retina (inner layer) and the retinal pigmented epithelium (outer layer) (reviewed in 
Chow and Lang, 2001). In human and mouse TBX2/Tbx2*, TBX3!Tbx3 and TBX5!Tbx5 are 
expressed asymmetrically across the neural retina with high levels of the transcripts detected 
in the dorsal and peripheral regions (Sowden et al., 2001 ). The BMP4 signalling pathway 
plays an important role in the patterning of the optic cup, where its expression pattern in the 
dorsal neural retina overlaps with that of the Tbx2 subfamily members, Tbx2, Tbx3 and Tbx5 
(Behesti et al., 2006). To test whether BMP4 signalling is able to regulate the expression of 
these T-box genes during eye development, a combination of whole mouse embryo cultures 
and bead implantation experiments were performed. In this study, beads soaked in BMP4 or 
the BMP antagonist, Noggin, were implanted into whole mouse embryos across the dorsal-
ventral axis of the optic cup. Exogenous BMP4 protein resulted in the expansion of the zone 
of Tbx2 and Tbx3 expression into the ventral retina, while the expression pattern of Tbx5 
remained restricted to the dorsal retina. However, while Noggin abolished Tbx5 expression it 
only reduced expression of Tbx2 while having no affect on Tbx3. The response of Tbx2, Tbx3 
and Tbx5 to BMP4 signalling was therefore different for each T-box gene, suggesting that the 
effect of BMP4 signalling varies across the optic cup. Furthermore, increasing the level of 
BMP4 signalling not only resulted in a decrease in proliferation but also in alterations in the 
growth and shape of the eye. Considering the proliferative role previously identified for Tbx2 
and Tbx3 during development it is tempting to suggest that as downstream targets of BMP4 
they may also be important in regulating the proliferation and development of the eye (Behesti 
et al., 2006). 
Bone Development 
Tbx2 has been shown to regulate expression of the genes encoding connexin (Cx) 43 (as 
mentioned earlier in heart development) and collagen, which are factors involved in bone 
formation. Gap junctions, composed of connexin (Cx) protein subunits, function to connect 
the cytoplasm of adjacent bone (osteocytes) cells and are therefore important in cell-cell 
communication. Cx43 is the predominant gap junction protein in bone and its regulated temporal 
pattern of expression has been shown to play a critical role in normal ossification and osteoblast 
function (Lecanda et al., 2000). Tbx2 and Cx43 are expressed in osteogenic progenitors and 
osteoblasts, which suggested that Cx43 may be a potential Tbx2 target gene. This was tested 
in a study in which a rat osteosarcoma cell line was transfected with either sense or anti-sense 
Tbx2 and the results showed that inhibition of Tbx2 resulted in a marked increase in Cx43 
expression (Berke et al., 2003; Chen et al., 2004). The Cx43 promoter has several T-element 
half sites and Tbx2 was shown to directly bind and repress the Cx43 promoter at two of these 
sites (Chen et al., 2004 ). Interestingly, in the same study transgenic mice injected with the LacZ 
reporter cloned downstream of either the wild-type (WT) or mutant Cx43 promoter in which the 
two T-elements were mutated exhibited the same expression pattern of LacZ (Chen et al., 2004 ). 
These results suggest that in vivo, Tbx2 may require other factors to regulate Cx43 expression. 
It is also important to note that these studies were done in mouse and rat, suggesting that 
the role of Tbx2 during bone development may vary between species. Recent studies have 
implicated the mouse Type 1 collagen gene as a potential Tbx2 target (Chen et al., 2001). 
11 
Type 1 collagen synthesis is crucial for normal embryonic development and in maintaining 
tissue integrity, and its aberrant expression has deleterious effects on several biological. 
processes including bone development (reviewed in Bornstein and Sage, 1989). In an attempt 
to identify genes that may be regulated by Tbx2, eDNA microarray analysis was performed on 
mouse NIH 3T3 fibroblasts overexpressing Tbx2 and results revealed that the type 1 collagen 
gene was upregulated (Chen et al., 2001 ). Interestingly, a parallel investigation in which Tbx2 
was overexpressed in the rat ROS17/2.8 osteoblastic cell line showed downregulation of type 
1 collagen (Chen et al., 2001 ). A recent study in our laboratory showed that TBX2 was able to 
repress a2(1) collagen expression independent of a T-element, suggesting that TBX2 may be 
acting as a co-repressor in these studies (Teng et al., 2007). Taken together, these contrasting 
results suggest that Tbx2 may regulate type 1 collagen genes by functioning as either co-
activator or co-repressor depending on the cell context and/or the species. 
Limb and Digit Development 
The development of the vertebrate limb begins with the formation of the limb primordium (limb 
bud) which is strategically positioned in the embryo, enabling it to receive and interpret a 
tightly regulated network of factors which provide positional cues. The limb bud, composed 
of mesenchymal cells, is surrounded by an ectodermal layer which extends out of the body 
wall. Interactions between the epithelial and mesochymal cell layers govern the growth and 
patterning of the limb bud (reviewed in Capdevila and lzpisua Belmonte, 2001 ). The mature 
limb is a complex structure composed of many tissue types such as bone, muscle and tendon 
(reviewed in Logan, 2003). Many genes required for limb development are expressed in 
identical patterns in both the developing forelimb and hindlimb, which raises the question 
of which genes are required for specifying limb-:type identity. Recent studies have begun to 
explain how genes that specify limb-type identity interact with signalling cascades common to 
both forelimb and hindlimb. 
Tbx2. Tbx3. Tbx4 and Tbx5 are expressed in developing mouse limbs either at the time of limb 
field specification, during limb bud outgrowth, or both (Chapman et al., 1996; Gibson-Brown 
et al., 1996). The temporal and spatial expression patterns of Tbx4 and Tbx5 are primarily 
restricted to the developing hindlimb and forelimb, respectively (Gibson-Brown et al., 1996; 
reviewed in Ruvinsky and Gibson-Brown, 2000), which is consistent with their having roles 
in specifying limb-type identity. The roles of Tbx4 and Tbx5 seem to be tightly linked to the 
activity of the signalling proteins FGF, BMP and Wnt which are required for limb outgrowth and 
patterning (Rodriguez-Esteban et al., 1999). 
The spatial and temporal expression of Tbx2 and Tbx3 along the anterior and posterior margins 
of the fore-and hindlimb buds is generally very similar in mouse and chick (Chapman et al., 
1996; Gibson-Brown et al., 1996; Gibson-Brown et al., 1998; Isaac et al., 1998; Logan et al., 
1998). A study by Suzuki et al. (2004) shows that Tbx2 and Tbx3 play an important role in the 
determination of digit identity in chick. Tbx3 was found to be important in the specification of 
digit Ill, while both Tbx2 and Tbx3 were required for digit Ill and IV identity. Furthermore, in 
this study the investigators showed that dominant negative forms of Tbx2 and Tbx3 lead to 
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reduced levels of Shh and that conversely, misexpression of Tbx2 induced anterior expansion 
of Shh expression. It is important to note that normal patterning of the developing limb requires 
the confinement of Shh expression to the posterior margin of the limb bud and thus the study 
by Suzuki et al. (2004) would suggest that Tbx2 and Tbx3 play an important role as a positive 
regulator of Shh expression within the posterior limb bud. In a very recent study, Nissim et 
al. (2007) also make a very strong case in favour of Tbx2 being responsible for limiting Shh 
expression to the margins of the limb bud. In the presence of cyclopamine, a Shh inhibitor, the 
expression of Tbx2 was unaffected in the anterior and posterior margins of the limb bud. In the 
same study, the investigators identified a novel ectodermal signalling centre, which was found 
to be sufficient to induce and maintain the expression of Tbx2 in the underlying mesoderm of 
the limb. Furthermore, they show that grafting the ectodermal signalling centre from the anterior 
margin to the dorsal region of another limb induced the anterior expansion of Shh. These 
results suggest that signals from the ectodermal signalling centre induce expression of Tbx2 
which regulates Shh expression in the posterior margin of the limb. Taken together, this is in 
keeping with the observation that in the human ulnar-mammary syndrome, haploinsufficiency 
of TBX3 leads to limb defects, which corresponds with that seen when Shh expression is 
reduced or absent (Bamshad et al., 1997; Davenport et al., 2003). These experiments beg the 
question of how Tbx2 and Tbx3 are regulated during limb development, which would be an 
important direction for future studies. 
Mammary gland Development 
Both Tbx2 and Tbx3 have been implicated in the development of the mammary glands in mice 
and humans (reviewed in Rowley et al., 2004). Both factors are expressed in the developing 
mammary glands of mice, where they are expressed in specific spatiotemporal patterns in 
the mesodermal and epithelial cell layers (Chapman et al., 1996; reviewed in Rowley et al., 
2004 ). During the emergence of the mouse mammary placodes, Tbx2 is expressed in the 
underlying mesodermal cells, while Tbx3 is expressed only in the epithelial cells. Interactions 
between the epithelial and mesodermal cell layers are known to govern induction and 
development of the mammary glands, suggesting a role for Tbx2 and Tbx3 in the induction 
of the mammary placodes and specification of mammary identity (reviewed in lmagawa et 
al., 2002 and Hennighausen and Robinson, 2001 ). The importance of Tbx3 during mammary 
development is demonstrated by the fact that homozygote mice fail to induce formation of the 
mammary glands (Davenport et al., 2003) while heterozygotes exhibit hyoplasia and nipple 
abnormalities (Bamshad et al., 1997, 1999). Furthermore, individuals suffering from ulnar-
mammary syndrome are prone to breast abnormalities which include absent areola, inability 
to lactate and mild hypoplasia of the breast. It is important to note that the expression of Tbx2 
and Tbx3 in mammary gland tissue persists into adulthood (reviewed in Rowley et al., 2004). 
This implicates them in the entire process of mammary gland development and renewal as 
these glands are constantly undergoing changes depending on a female's state of puberty, 
pregnancy, lactation or involution. Compared to Tbx3, the role of Tbx2 in the development of 
the mammary glands is less well defined. However, the defects in Tbx3 heterozygous mice are 
exacerbated in Tbx2, Tbx3 double heterozygote mice which not only suggest a role for Tbx2 in 
mammary gland development but also imply a genetic interaction between these two factors 
(Jerome-Majewska et al., 2005). 
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Melanocytes 
Tbx2 expression has been observed in several melanocyte and melanoma cell lines but not in 
pre-melanoblast cells (Carreira et al., 1998). Melanoblasts are neural crest derived cells which 
migrate to the hair follicles and epidermis where they differentiate into mature melanocytes 
capable of producing pigment (Silvers, 1979). The microphthalmia associated transcription 
factor, MITF, a member of the helix-loop-helix leucine zipper class, has been identified as a 
key regulator of melanocyte development (Hodgkinson et al., 1993; reviewed in Levy et al., 
2006). MITF was shown to be involved in melanocyte differentiation, proliferation and survival. 
To date, the MITF target genes identified encode proteins involved in pigmentation including 
tyrosinase and tyrosinase-related protein 1 {TRP-1) (Bentley et al., 1994; Ganss et al., 1994; 
Hemesath et al., 1994; Yasumoto et al., 1994; Yasumoto et al., 1995; Yavuzer et al., 1995). 
Interestingly, MITF was found to bind and activate the expression of Tbx2 which raises the 
question of what the role of Tbx2 is in melanocytes (Carreira et al., 2000). Since Tbx2 is not 
involved in melanin production one might expect that as a MITF target it may be involved in the 
other functions of MITF such as melanocyte proliferation and/or survival. The fact that Tbx2 
is expressed after the cells have committed to the melanocytes lineage (Carreira et al., 1998) 
also suggests that Tbx2 may play a role in the maintenance of melanocyte identity. 
1.3.3 Role of Tbx2 in the regulation of the cell cycle and cancer 
There is a significant amount of evidence pointing to a role for Tbx2 and Tbx3 in cell cycle 
regulation and cancer. Both TBX2 and TBX3 gene expression have been found to be de-
regulated in a number of cancers, including breast (Sinclair et al., 2002; Fan et al., 2004), 
pancreatic (Mahlamaki et al., 2002; Hansel et al., 2004), melanoma (Vance et al., 2005; Hoek 
et al., 2004), liver (Renard et al., 2007) and bladder (Ito et al., 2005) cancers. 
TBX2 and TBX3, as mentioned earlier, are involved in normal breast development and studies 
have shown that their altered expression may play a role in the pathogenesis of breast cancer. 
TBX2 was shown to be amplified and overexpressed in a subset of breast cancer cell lines and 
primary tumours. Using fluorescence in situ hybridization, TBX2 was shown to be amplified 
in BRCA1- and BRCA2-related breast tumours (Jacobs et al., 2000; Sinclair et al., 2002). 
Furthermore, in situ hybridization of paraffin sections from sporadic and hereditary breast 
tumours confirmed that this amplification was a result of increased TBX2 gene expression 
(Sinclair et al., 2002). Similarly, TBX3 is amplified in a subset of breast cancer cell lines (Fan et 
al., 2004) and was shown compared to non-cancer patients to be upregulated in plasma from 
breast and ovarian cancer patients (Lomnytska et al., 2006). Both TBX2 and TBX3 have also 
been associated with pancreatic cancer. While TBX2 was found to be overexpressed in 50% of 
thirty one pancreatic cancer cell lines tested (Mahlamaki et al., 2002), TBX3 was shown to be 
upregulated in metastatic pancreatic endocrine neoplasms (Hansel et al., 2004). Importantly, 
TBX2 maps to chromosomal band 17q23 (Law et al., 1995), which is frequently amplified in 
many breast and pancreatic cancer cells (Wu et aL, 2001, Sinclair et al., 2002; Barlund et al., 
2000; Mahlamaki et al., 2002). Furthermore, both TBX2/Tbx2 and TBX3 are expressed in 
normal melanocytes and have been found to be strongly upregulated in a subset of melanoma 
cell lines (Carreira et al., 1998; Vance et al., 2005; Hoek et al., 2004). Dosage sensitivity of 
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TBX2 and TBX3 has also been associated with other cancers. TBX2, which is expressed in 
normal human fibroblasts, was recently shown to be downregulated in several transformed 
fibroblast cell lines (Teng et al., 2007), while TBX3 was found to be upregulated in transformed 
lung fibroblast cells (Yin et al., 2004). Although the above findings suggest an association of 
both TBX2 and TBX3 with tumourigenesis, they do not provide a mechanism(s) for how these 
T-box genes contribute to the oncogenic process. 
A possible mechanism for how TBX2 and Tbx3 may contribute toward the oncogenic process 
is suggested by studies which have shown that they are both able to function as immortalising 
genes that enable the cells to bypass senescence (Jacobs et al., 2000; Carlson et al., 2001 ). 
Cell senescence is broadly defined as the physiological program of irreversible growth arrest 
which can be triggered by shortening of the telomeres (replicative senescence) or by different 
forms of stress (accelerated senescence) (reviewed in Roninson, 2003). The main mediators 
of senescence are the cyclin dependent kinase inhibitors (Cdkis), p21 and p161NK4a, with p21 
thought to be necessary for initiating the senescence-like growth arrest and p161NK4a required for 
maintenance of the state (Stein et al., 1999). The induction of p21 appears to be largely p53-
dependent and the Cdki, p19ARF, has also been shown to initiate a senescent-like growth arrest 
by stabilising p53 protein levels (reviewed in Roninson, 2003). Senescence is thought to be an 
important protective mechanism against cancer as neoplastic transformation appears to result 
from events that inhibit the program of senescence. Using two different cell culture models of 
senescence, investigators have shown that both Tbx2 and Tbx3 can behave as immortalising 
genes by preventing senescence. Primary mouse embryonic fibroblasts (MEFs) deficient for 
the proto-oncogene Bmi1 ordinarily undergo premature senescence which is bypassed when 
they are infected with retroviral vectors expressing either TBX2 or TBX3 (Jacobs et al., 2000; 
Brummelkamp et al., 2002). Similar results were observed using a mouse striatum cell line (ST. 
Hdhq111 ) expressing a temperature-sensitive SV40 T-antigen which allows them to proliferate 
at 33°C but to senesce at 39°C. In these experiments, when the ST.Hdhq111 cells were infected 
with either a Tbx2 or TBX3-expressing retrovirus they fail to undergo senescence at 39°C 
(Brummelkamp et al., 2002; Prince et al., 2004). In the above studies TBX2 and TBX3 were 
shown to prevent senescence by a mechanism involving their ability to transcriptionally repress 
p19ARF (mouse homologue of the human p14ARF) and p21 (Jacobs et al., 2000; Brummelkamp 
et al., 2002; Lingbeek et al., 2002; Prince et al., 2004 ). The possibility that Tbx2 may contribute 
to the oncogenic process by inhibiting senescence is supported by a study that showed that 
expressing a dominant-negative Tbx2 in 816 mouse melanoma cells led to increased levels of 
p21 and induction of senescence (Vance et al., 2005). 
Another possible mechanism by which Tbx3 may contribute to oncogenesis is through inhibiting 
the p19ARFJMdm2/p53 pathway. In response to abnormal mitogenic signalling, activation of 
oncogenes such as Myc and Ras stimulate the p19ARFJMdm2/p53 pathway. Briefly, aberrant 
mitogenic signalling leads to increased p19ARF levels which results in p19ARF sequestering the 
ubiquitin ligase murine double minute (Mdm2), thus preventing ubiquitin-mediated degradation 
of the p53 protein. Once activated, p53 transcriptionally regulates a set of genes involved in cell 
cycle arrest, DNA repair or apoptosis (Zindy et al., 1998; Palmero et al., 1998; reviewed in Sherr 
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and Weber, 2000). Interestingly, Tbx3 was found to cooperate with oncogenic Myc and Ras to 
efficiently transform MEFs, which correlated with an ability of Tbx3 to suppress the induction of 
p19ARF and p53 protein levels (Carlson et al., 2002). In the same study, ectopic Tbx3 expression 
was shown to protect MEFs against Myc-induced apoptosis. Additional support for the ability of 
Tbx3 to block apoptosis was demonstrated when Tbx3 was silenced in rat bladder carcinoma 
~ells and apoptosis was induced (Ito et al., 2005). Furthermore, Renard et al. (2007) showed 
both in vitro and in vivo that human liver tumour cells stably transfected with dominant negative 
TBX3 exhibited severely reduced proliferation and tumour growth. Moreover, silencing TBX3 
using siRNA inhibited anchorage independence and failed to protect cells against apoptosis. 
Taken together all the above information suggests that Tbx2 and Tbx3 may play an important 
role in cell cycle regulation. If this were the case then one might expect the protein levels of 
Tbx2 and Tbx3 to be regulated during the various phases of the cell cycle. Indeed, Bilican and 
Goding (2006) showed that Tbx2 protein levels are regulated during the cell cycle, with levels 
peaking at G2 and the protein being almost undetectable in mitosis. The observation that Tbx2 
protein levels peak at G2 points to a possible role for Tbx2 during the G2/M transition of the cell 
cycle. Indeed, a recent investigation in our laboratory has provided evidence for a functional 
role for TBX2 during G2/M (Davis et al., 2007). Ectopic expression of TBX2/Tbx2 in a fibroblast 
and a melanoma cell line was shown to lead to a number of mitotic defects. FAGS analysis of 
the TBX2/Tbx2 expressing cells showed they are initially arrested in G2/M but then acquire 
the ability to override the block and re-enter the cell cycle with a DNA content of 8n. Compared 
to the parental cells the TBX2/Tbx2 expressing cells displayed increased features of genomic 
instability, such as chromosome doubling, chromosomal rearrangements and polyploidy. 
The ability of TBX2/Tbx2 to override the checkpoint controls resulting in genomic instability 
may provide an additional mechanism by which TBX2/Tbx2 contributes to tumourigenesis. 
Furthermore, the studies by Bilican and Goding (2006) and Davis et al. (2007) both highlight 
the importance of the need for TBX2/Tbx2 protein levels to be tightly regulated during the cell 
cycle. Interestingly, the study by Bilican and Goding (2006) also shows that changes in Tbx2 
protein levels are not matched by changes in Tbx2 mRNA levels, suggesting that the protein 
may be regulated by post-translational modifications such as phosphorylation. A major aspect 
of the current thesis was to investigate whether the Tbx2 protein is indeed phosphorylated and 
regulated by the cyclin dependent kinases and hence the next section will provide an overview 
of the key areas relevant to the research presented. 
1.4 The eukaryotic cell cycle 
The eukaryotic cell cycle, which is divided into the G1, S, G2 and M phases, represents a series 
of tightly regulated events that allows the cell to duplicate its genetic material and divide into 
two identical daughter cells. The major events that need to be regulated are DNA synthesis (S 
phase) and the equal separation of the duplicated chromosomes between two daughter cells 
(M or mitosis) (Fig. 1.3) (reviewed in Tessema et al., 2004). G1 and G2 are the checkpoints 
that control the order and timing of cell cycle transitions and ensure that the events of S and 
M are completed with high fidelity. In G1, the cell size is monitored, while in G2 the replicated 
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Figure 1.3. The eukaryotic cell cycle. The cell cycle is divided into four phases (G1, S, G2 and 
M). Progression through the different phases of the cell cycle is mediated by cyclin dependent 
kinases (Cdk), which are positively regulated by cyclins and negatively regulated by cyclin 
dependent kinase inhibitors (Cdki). 
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to G1 and G2 there is also the spindle assembly checkpoint (SAC) in mitosis that monitors 
the successful completion of the metaphase-to-anaphase transition. SAC ensures that the 
mitotic chromosomes are correctly aligned on the mitotic spindle and that the sister chromatids 
are properly separated to opposite ends of the poles. All three checkpoints are also able to 
respond to DNA damage and if triggered will arrest the cell in order to for example, allow the 
cell time to repair the DNA. Checkpoint loss results in genomic instability which is an important 
hallmark of several cancers. 
1.4.1 Cyclins, cyclin dependent kinases (Cdks) and cdk inhibitors (Cdkis) 
Progression through the different phases of the cell cycle is mediated by two classes of protein, 
the cyclins and Cdks (reviewed in Pines, 1995 and Morgan, 1997). Cdks are serine/threonine 
kinases that are activated during specific stages of the cell cycle and are often referred to as 
the engines that drive the cell cycle. In mammals, 11 Cdks have been identified, although only 
five (Cdk1, Cdk2, Cdk3, Cdk4 and Cdk6) have been directly implicated in the regulation of 
the cell cycle (reviewed in Malumbres and Barbacid, 2005). Activation of Cdks is dependent 
on binding to a regulatory subunit called cyclins which, as the name suggests, are proteins 
characterised by their tightly regulated appearance and disappearance during the cell cycle, 
which are controlled by precise transcription and proteolytic events. Degradation of the cyclins 
involves a sequence within their N-termini called the destruction box (D-box) and studies have 
shown that deletion or introduction of point mutations within the D-box inhibits their proteolytic 
degradation (Glatzer et al., 1991; Yamane et al., 1998; Geley et al., 2001 ). The destruction 
of the cyclins occurs by ubiquitination within the D-box, which targets them for proteolytic 
degradation (reviewed in Fung and Peon, 2005). 
Association of Cdks with their appropriate cyclins regulates progression through the phases 
of the cell cycle (Fig. 1.3) by phosphorylating substrates required for the events of specific 
phases. For example, progression through G1 is regulated by cyclin D/Cdk4/6, G1/S transition 
by cyclin E/Cdk2, S phase by cyclin A/Cdk2 and entry into M requires both cyclin A/Cdk2 and 
cyclin B/Cdk1 (reviewed in Morgan, 1997 and Schwartz and Shah, 2005). In the absence 
of appropriate mitogenic stimuli or in response to DNA damage, the cell is arrested at any 
one of the checkpoints mentioned above by the Cdk inhibitors (Cdkis) (reviewed in Elledge, 
1996 and Sherr and Roberts, 1999). Two families of Cdkis have been identified, namely the 
Kip/Cip proteins (p21, p27K1P1 and p57K1P2) and the INK proteins (p161NKa, p151NKb, p181NKc and 
p191NKd). The Kip/Cip family of inhibitors form a ternary structure with cyclin/Cdk complexes 
containing cyclins D, E and A, while the INK family prevent assembly of the Cdk with the cyclin 
and selectively binds cyclin D/Cdk4 or 6. The kinase activity of Cdks is therefore regulated by 
Cdkis, together with specific phosphorylation and dephosphorylation events, while the cyclins 
are tightly regulated both transcriptionally and by ubiquitin-dependent degradation. 
As mentioned earlier in 1.3.3, Tbx2 levels peak at G2 and it appears to have a role in either 
G2 and/or the transition from G2 to M. If this is the case it would be expected to be a substrate 
for the cyclin/CDK complexes that regulate these phases. The next section will therefore deal 
specifically with the cyclin A/Cdk2 and cyclin B/Cdk1 complexes. 
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1.4.2 Regulation of the transition from G2 to M by cyclin A/Cdk2 and cyclin 8/ 
Cdk1 
The production of two identical daughter cells during mitosis occurs in five phases: prophase, 
prometaphase, metaphase, anaphase and telophase (reviewed in Pines and Rieder, 2001 and 
Ferrari, 2006). At the end of S phase when DNA has been replicated, sister chromatids are 
held together by kinetochores at their centromeric regions and by cohesins along their entire 
length. Very briefly, chromatin condensation, which coincides with histone H3 phosphorylation, 
occurs during prophase. Nuclear envelope breakdown which occurs at the time of transition 
to prometaphase is facilitated by phosphorylation of the nuclear lamins. At the same time 
spindle microtubules make contact with kinetochores at the chromatids. As the cell approaches 
metaphase, the chromosomes begin to move to the equator of the spindle apparatus, where 
they align along the metaphase plate. During anaphase the sister chromatids move to opposite 
poles of the spindle by the shortening of the microtubules that are attached to kinetochores. 
Mitosis is concluded at telophase with the reformation of the nuclear membrane around 
decondensing chromosomes. This is followed by the cleavage and separation of the two 
daughter cells during cytokinesis. 
Cyclins A and 8 are regarded as the mitotic cyclins as they are important in regulating the entry 
into and exit from mitosis. In mammalian cells, there are two types of A cyclins, namely A 1 and 
A2 and three types of 8 cyclins (81, 82 and 83) (reviewed in Fung and Poon et al., 2005). 
Cyclin A 1 is only expressed during meiosis, while cyclin A2 is expressed in all proliferating 
somatic cells. Of the three 8-type cyclins, only cyclin 81 is associated with mitosis. Cyclin 83 
is restricted to the developing germ line cells and the adult testis, and while cyclin 82 is co-
expressed with cyclin 81 it is localised to the Golgi apparatus and does not seem to have a 
recognised role as yet. 
It is well established that cyclin 81 protein forms a complex with Cdk1 which, when activated, 
initiates the entry, transition and exit from mitosis by phosphorylating numerous substrates 
(reviewed in Nigg, 2001 and Ferrari et al., 2006). These include proteins that control 
chromosome condensation such as condensins, nuclear lam ins (the phosphorylation of which 
leads to nuclear envelope breakdown), microtubule binding proteins and kinesin-related motor 
proteins, which are involved in centrosome separation and spindle assembly. Exit from mitosis 
is regulated by anaphase-promoting complexes/cyclosome (APC/C) which targets cyclin 81 
and mitotic kinases such as securin, aurora-A and -8 among others for proteolytic degradation 
(Sudakin et al., 1995; Zachariae et al., 1998; reviewed in Harper et al., 2002 and Peters, 2002). 
A major requirement for transition from metaphase to anaphase is the degradation of cyclin 
81 through the activity of APC/C which, interestingly, is a target of cyclin 81/Cdk1 (reviewed in 
Fung and Poon, 2005). 
As mentioned earlier, cyclin A/Cdk2 has a dual role in the regulation of the S and M phases 
of the cell cycle. During mitosis, cyclin A can also associate with both Cdk1 and Cdk2 but the 
cyclin A/Cdk2 complex is the most active and abundant of the two complexes (Pagano et al., 
1992, 1993; Rosenblatt et al., 1992). Once active, cyclin A/Cdk2 is thought to promote entry into 
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mitosis by promoting the activation of cyclin B1/Cdk1 (Guadagno and Newport, 1996; Lukas et 
al., 1999). This possibility was supported by results from a study by Gong et al. (2007) which 
showed that when cyclin A was knocked down by RNAi, nuclear envelope breakdown did not 
occur and that cyclin B1 did not translocate to the nucleus. Furthermore, cyclin NCDK2 is also 
thought to be required for progression of cells up to mid-prophase because it was shown that 
once cells have replicated their DNA, cyclin NCDK2 promotes entry into mitosis and initiates 
chromatin condensation independent of cyclin B1/CDK1 (Furuno et al., 1999). 
1.4.3 Regulation of cyclin A/Cdk2 and cyclin B/Cdk1 
The activity of the cyclin NCdk2 and cyclin B/Cdk1 complexes is tightly controlled by the levels 
of the cyclin A and B 1 regulatory subunits, as well as by subcellular localisation and specific 
phosphorylation events on the Cdk1 and Cdk2 catalytic subunits. 
Levels of eye/in A and 81 
Cyclin A starts to accumulate during G1 with levels peaking in G2 and the protein is degraded 
at metaphase (den Elzen and Pines, 2001; Geley et al., 2001; Pines and Hunter, 1990, 1991; 
Clute and Pines, 1999). Cyclin B1 protein accumulates at G2 and is degraded slightly later 
than cyclin A at the metaphase-anaphase transition. Both cyclin A and B 1 possess an N-
terminal region called the D-box which targets them to the APC/C complex for ubiquitination 
(reviewed in Fung and Poon, 2005). Despite the fact that cyclin A and B1 are degraded by the 
same mechanism it is not clear why these two cyclins are degraded at slightly different times. 
It has however been proposed that variations in the D-box may account for the difference in 
the destruction of the mitotic cyclins. The D-box of cyclin A is 10-20 residues longer than that 
of cyclin B1 (Geley et al., 2001) and it has been proposed that the extended D-box may alter 
the substrate specificity of cyclin A thus influencing the timing of its destruction (reviewed in 
Fung and Poon, 2005). A study by den Elzen and Pines, (2001) has further demonstrated that 
degradation of human cyclin A occurs independently of the D-box. It would therefore appear 
that while the D-box is sufficient to degrade cyclin B1, additional mechanism(s) are required 
for the timely destruction of cyclin A. 
Subcellular localisation of eye/in A/Cdk2 and eye/in B1/Cdk1 
During interphase, cyclin B 1 /Cdk1 is predominantly localised in the cytoplasm by the cytoplasmic 
retention signal (CRS), which is located in the N-terminus of the cyclin B1 protein (Pines and 
Hunter, 1994). In addition, the cytoplasmic localisation of cyclin B1 during interphase also 
results from its export out of the nucleus, which involves a leucine-rich nuclear export signal 
(NES) which acts togetherwith the export receptor CRM1/exportin 1 (Toyoshima et al., 1998; 
Hagting et al., 1998; Yang et al., 1998). Based on experiments that have shown that treatment 
with leptomycin B, an inhibitor of CRM1-mediated export, leads to a significant increase in the 
nuclear accumulation of cyclin B1, it has been proposed that cyclin B1 shuttles continuously 
between the cytoplasm and nucleus and that during interphase, the rate of export out of the 
nucleus exceeds the rate of import into the nucleus {Toyoshima et al., 1998; Hagting et al., 1998; 
Yang et al., 1998). Furthermore, at the onset of mitosis cyclin B1 is phosphorylated at four serine 
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residues within the CRS which reduces the affinity of cyclin 81 for the CRM1 export receptor, 
thereby reducing nuclear export and promoting· nuclear accumulation (Li et al., 1997; Yang et 
al., 1998). Interestingly, Bassermann et al. (2005) have identified an additional mechanism 
that regulates the nuclear accumulation of cyclin 81. In their study they identified a novel E3 
ubiquitin ligase, SCFNIPAwhich was shown to bind and target nuclear cyclin 81 for ubiquitination 
during interphase. In late G2, however, phosphorylation of SCFNIPA by an as yet unidentified 
kinase(s) results in its disassociation from cyclin 81, resulting in the nuclear accumulation of 
cyclin 81 and entry into mitosis. The importance of SCFNIPA was further demonstrated in the 
same study where cells treated with siRNA against SCFNIPA exhibited elevated levels of nuclear 
cyclin 81, premature entry into mitosis and a mitotic arrest at prometaphase (Bassermann et 
al., 2005). Taken together, the above studies suggest that the regulation of the subcellular 
localisation of cyclin B 1 is complex and that it is probably regulated at multiple levels. 
As is the case for cyclin B 1, cyclin A also shuttles continuously between the nucleus and the 
cytoplasm. However the rate of cyclin A import into the nucleus exceeds the rate of its export 
(Jackman et al., 2002) and therefore it appears to be predominantly nuclear throughout the 
cell cycle. Importantly, while the mechanism by which cyclin A is exported from the nucleus is 
poorly understood, nuclear import of cyclin A is dependent on its association with CDK2. 
Phosphorylation and dephosphorylation of eye/in A/Cdk2 and eye/in B1/Cdk1 
Activation of the cyclin B1/Cdk1 complex has been proposed to happen by a series of 
phosphorylation and dephosphorylation events. As previously mentioned, cyclin 81 is 
synthesised during interphase where it associates with its catalytic subunit Cdk1. The cyclin 
B1/Cdk1 complex is kept inactive by phosphorylation of Cdk1 at Thr14 and Tyr15 by the 
inhibitory kinases, MYT1 and WEE1 (reviewed in Dunphy, 1994 and Morgan, 1997). While 
MYT1 can phosphorylate both Thr14 and Tyr15 (Mueller et al., 1995; Booher et al., 1997; Liu et 
al., 1997) WEE1 phosphorylates only Tyr15 (Heald et al., 1993; McGowan and Russell, 1993; 
Parker and Piwinica-Worms, 1992). At the G2/M transition, dephosphorylation at both Thr14 
and Tyr15 by the Cdc25 phosphatase promotes activation of the cyclin B1/Cdk1 complex and 
entry into mitosis (reviewed in Dunphy, 1994; Lew and Kornbluth, 1996 and Takizawa and 
Morgan, 2000). Full activation of the complex is achieved by phosphorylation at Thr161 by the 
Cdk-activating kinase (CAK) (Solomon et al., 1992, 1993), while de-phosphorylation at this 
residue by KAP (CAK-associated phosphatase) returns the kinase to its inactive state in G1 
(Hannon et al., 1994). 
Activation of the cyclin A/Cdk2 complex also requires a series of phosphorylation and 
dephosphorylation events. Similar to cyclin B1/CDK1, Cyclin A/CDK2 is kept inactive by 
phosphorylation of CDK2 on Thr14 and Tyr15 prior to entry into mitosis (Gu et al., 1992). Full 
activation of the complex is achieved by phosphorylation of Thr160 by the CAK together with 
dephosphorylation of CDK2 at Thr14 and Tyr15 by the CDC25 phosphatase (Gu et al., 1992). 
Dephosphorylation of Thr160 by KAP inhibits the Cdk2 activity upon subsequent association 
with cyclin A (Poon and Hunter, 1995; reviewed in Lew and Kornbluth, 1996). 
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1.5 Signal transduction pathways 
Signal transduction cascades mediate the sensing and subsequent movement of signals 
from the outside of the cell to the inside. These signalling cascades require an ordered 
sequence of biochemical reactions to detect, amplify and finally translate the signal into a 
specific cellular response, such as changes in gene expression and enzyme activity. One of 
the most critical post-translational modifications controlling the regulation of cellular events 
in response to signalling is reversible protein phosphorylation at specific serine, threonine 
or tyrosine residues. The process of reversible phosphorylation is controlled by kinases and 
phosphatases which represent a significant portion of the human genome, highlighting the 
importance of these enzymes in the regulation of key cellular processes (reviewed in Manning 
et al., 2002). The mitogen-activated protein (MAP) kinases represent one of the most important 
and well characterised families of kinases, which catalyse the phosphorylation of a wide range 
of substrates in response to diverse stimuli (reviewed in Robinson and Cobb, 1997). 
1.5.1 Mitogen-activated protein (MAP) kinase family 
MAP kinases are activated via a highly conserved phospho-relay system composed of three 
sequentially activated protein kinases (Fig. 1.4a). The first kinase in this cascade is the MAP 
kinase kinase kinase (MAPKKK) which, in response to a specific stimulus, phosphorylates 
and activates the dual-specificity MAP kinase kinase (MAPKK) at specific serine/threonine 
residues. MAPKK in turn phosphorylates MAP kinase at threonine and tyrosine residues within 
the Thr-Xaa-Tyr motif, which is essential for complete activation of the MAP kinase. Once 
activated, the proline-directed serine/threonine MAP kinase phosphorylates a range of target 
proteins, many of which are transcription factors, cytoplasmic substrates and other kinases 
(reviewed in Robinson and Cobb, 1997 and Garrington and Johnson, 1999). 
The MAP kinase family is divided into four distinct subgroups: the extracellular signal-regulated 
kinases (ERKs), c-jun N-terminal or stress-activated protein kinases (JNKISAPK), ERK5/big 
MAP kinase 1 (BMK1) and the p38 group of protein kinases (Fig. 1.4b ). ERK family members 
are mainly activated by mitogenic stimuli, while the JNK and p38 MAP kinases are activated 
mainly in response to stress stimuli or inflammatory cytokines (reviewed in Roux and Blenis, 
2004 and Kyriakis and Avruch, 2001 ). The recently identified subgroup, ERK5, is activated 
by a combination of mitogenic stimuli and osmotic stress (reviewed in Wang and Tournier, 
2006). The four MAP kinase subgroups differ from one another structurally in two respects (Fig 
1.5). Firstly, the variable amino acid between the Thr and Tyr of the phosphorylation motif is a 
glutamate for ERK, proline for JNK and glycine for the p38 MAP kinases (reviewed in Ono and 
Han, 2000). Secondly, all three phosphorylation motifs form part of the linker loop 12 region 
and it is the length of the loop that varies among the different members of the MAP kinase 
family (Jiang et al., 1997b). In keeping with the focus of this thesis, the next section focuses on 
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Figure 1.4. The MAP kinase signalling pathways. (a) The MAP kinase phospho-relay system. 
MAP kinase pathways are composed of three kinases: a MAP kinase (MAPK), MAPK kinase 
(MKK), and a MAPK kinase kinase (MKKK). (b) The MAP kinase family consists of four major 
subgroups: ERK1/2, p38, JNK, and ERK5/BMK1 , which are activated through phosphorylation 
by their specific MAPKKs. MAPKKs are in turn activated through phosphorylation by their 
specific MAPKKKs in response to stimulation by growth factors, cytokines and cellular stress. 
Activated MAPKs phosphorylate various substrates including transcription factors, kinases and 
cytoskeletal proteins, which is critical for mediating the appropriate biological response. 
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Figure 1.5. Dual phosphorylation within the phosphorylation motif activates the MAP kinase. 
Phosphorylation at both the threonine and tyrosine residues within the phosphorylation motif 
(TXY) by the dual-specificity MAPKK activates the MAP kinase. Specific protein phosphatases 
inactivate the MAPK by dephosphorylating either one or both of the phosphorylated residues. 
The variable amino acid, X, may be either glutamate for ERK, proline for JNK and glycine for 
the p38 MAP kinase. 
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1.5.2 p38 MAP kinase signalling pathway 
The p38 MAP kinase (referred to as p38), also known as reactivating kinase (RK), cytokine 
synthesis anti-inflammatory drug (CSAID) binding protein (CSBP) or stress-activated protein 
kinase 2a (SAPK2a), is the mammalian homologue of the yeast HOG kinase (Rouse et al., 
1994; Lee et al., 1994). p38 was first identified as a 38 kDa protein (Han et al., 1993, 1994) 
and to date four primary isoforms of p38 have been characterised: p38a, p38j3, p38y and p388. 
The p38a and p3813 isoforms are ubiquitously expressed (Jiang et al., 1996), whereas p38y 
is predominantly expressed in skeletal muscle (Lechner, 1996; Li et al., 1996) and p388 is 
detected in the lungs, kidneys, testis, pancreas and small intestine (Kumar et al., 1997). More 
than 60% sequence identity exists between each isoform, with only 40-45% sequence identity 
observed among other MAP kinase members (Jiang et al., 1997a). Tissue distribution and/or 
expression patterns reflect differences in the regulation and functions of each p38 isoform. 
Once activated p38 has been shown to phosphorylate a range of protein kinases and 
transcription factors involved in both stress and non-stress cellular processes (reviewed in 
Zarubin and Han, 2005 and Nebreda and Porras, 2000). The cellular stresses that activate 
the p38 signalling pathway include osmotic shock, ultraviolet (UV) light, heat shock, protein 
synthesis inhibitors, inflammatory cytokines and liposaccharides (reviewed in Zarubin and 
Han, 2005). In response to cellular stress the p38 pathway impacts on a number of cellular 
processes including proliferation, survival, cell differentiation, the inflammatory response and 
apoptosis. p38 also plays a role in non-stress cellular processes, for example during embryonic 
development, differentiation, proliferation and survival of several cell types (reviewed in 
Bradham and McClay, 2006 and Nebreda and Porras, 2000). 
1.5.2.1 Regulation of the p38 MAP kinase 
While the total level of p38 protein remains unchanged, in response to a specific stimulus, 
phosphorylation at Thr180 and Tyr182 by the dual-specificity kinases MAPKK3, MAPKK4, 
MAPKK6 and MAPKK7 (Doza et al., 1995; Raingeaud et al., 1995; Derijard et al., 1995; Han 
et al., 1996) leads to increased levels of phosphorylated p38. This phosphorylation is often 
transient and results in rapid activation of p38. Despite the high degree of homology between 
the various p38 isoforms and the conserved dual phosphorylation site, they are selectively 
activated by different MAPKKs (Fig. 1.4b). For example, while MAPKK6 is able to activate 
all the p38 isoforms, MAPKK3 is unable to activate p3813 (Keesler et al., 1998) and MAPKK7 
has also been shown to activate p388 (Hu et al., 1999). Furthermore, MAPKK4, an upstream 
activator of JNK, has also been found to activate p38a and p388 in a cell-type specific manner 
(Jiang et al., 1997a). 
In response to several physiological stimuli, such as tumour necrosis factor (TNF) and CpG 
oligonucleotide treatment, p38a can also be activated by phosphorylation at Thr180 and Tyr182 
by transforming growth factor- 13-activated protein kinase 1 (TAB1) (Ge et al., 2002, 2003). 
When associated with TAB1, p38 therefore appears to be able to autophosphorylate itself. In 
contrast, a study using MAPKK3/6 knockout MEF cells showed that phosphorylation of p38 in 
· response to TNF and UV radiation was dependent on MAPKKs (Branche et al., 2003). 
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In addition, a third mechanism of activation for p38 has been identified in T cells. In response 
to T cell receptor stimulation, both ZAP-70 and Src family tyrosine kinases phosphorylate 
p38a and p3813 on Tyr323, which induces autophosphorylation at the dual phosphorylation 
sites (Salvador et al., 2005). These studies suggest that alternative activation pathways of 
p38 may exist in response to different physiological and pathological conditions. There are 
also additional mechanisms ensuring the efficacy and specificity of the signal transduced by 
the p38 kinase into the appropriate cellular response. These include scaffold proteins, docking 
interactions, subcellular distribution, protein phosphatases and cross-talk among MAP kinases 
and other signalling pathways. 
Scaffold proteins and Docking interactions 
Recent studies have identified scaffold proteins as playing an important role in regulating the 
activation of specific MAP kinase signalling pathways. Scaffold proteins ensure that specific 
signalling pathways are triggered by recruiting active enzymes into appropriate signalling 
cascades by local ising enzymes to specific subcellular compartments or substrates (reviewed 
in Whitmarsh and Davis, 1998). The p38 and JNK signalling pathways represent an example 
of where scaffold proteins play an important role in determining which pathway will be activated 
in response to cellular stress. The JNK Interacting Proteins (JIP) constitutes a family of scaffold 
proteins that interact with both the JNK and p38 pathways. The JIP proteins promote p38 
signalling by binding p38 directly or components of the p38 signalling pathway. For example, 
JIP2 is able to bind the p38a and p38y isoforms, MKK3 and the Rac-GTPase (Buchsbaum et 
al., 2002; Schoorlemmer and Goldfarb, 2001 ). The molecular mechanism of how JIP family 
members are able to selectively regulate both JNK and p38 are not known but one possibility 
is that JNK and the p38 isoforms may compete for binding to JIP proteins, thereby inhibiting 
the activation of each other (reviewed in Whitmarsh, 2006). 
Together with scaffold proteins, the efficacy and specificity of the protein-protein interactions 
between p38 and its interacting molecules and phosphatases are mediated by docking 
interactions. Docking interactions are distinct from the kinase catalytic centre and the dual 
phosphorylation motif (reviewed in Tanoue and Nishida, 2002, 2003). Briefly, two reciprocal 
docking sites on the surface of p38, called the common docking (CD) domain and the ED 
site, mediate binding to the docking (D) domain present in p38 activators and downstream 
substrates (Fig. 1.6). The CD domain is conserved among all MAP kinases at the C-termini and 
contains both acidic and hydrophobic amino acids (Tanoue et al., 2000). The acidic residues 
(Asp313, Asp315 and Asp316) in the human p38a interact with the positively charged residues 
in the D domain of p38 substrates and phosphatases. In addition to the CD domain, the ED 
site (Giu160 and Asp161 ), is also important in substrate recognition (Tanoue et al., 2001 ). 
Together, the CD domain and the ED site form the docking groove of p38 and each amino acid 
residue in the docking groove contributes differently to specific docking interactions (Tanoue 
et al., 2001 ). 
It is important to note that a subset of MAP kinase substrates also have a conserved motif 
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Figure 1.6. Schematic representation of the docking domains of MAPKK, MAPK and the 
MAPK substrate. The positively charged residues in the docking (D) domain interact with the 
common docking (CD) domain and ED site in the C-terminal region of the MAP kinase. The CD 
and ED site form a docking groove where each amino acid in the groove contributes differently 
to each docking interaction. 
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efficient phosphorylation by MAP kinases including p38 (Galanis et al., 2001 ). Residues within 
the activation loop of MAP kinases have also been found to be important in substrate specificity. 
For example, MKK3 does not possess aD domain and yet is able to activate p38a, p38y and 
p385 but not p38f3 (Enslen et al., 2000). Interestingly, when the activation loop of p38f3 was 
mutated into a p38a, p38y and p385-like activation loop it was activated by MKK3. These 
results suggest that residues within the activation loop are also able to promote activation of 
the p38 isoforms (Enslen et al., 2000). 
Subcellular localisation 
Given the fact that p38 phosphorylates various substrates in distinct cellular compartments, 
controlling its subcellular localisation is important. Despite the evidence for the nucleocytoplasmic 
shuttling of p38, no NLS or nuclear export signals (NES) have been identified for p38 or other 
members of the MAP kinase family. Furthermore, no direct interactions between MAP kinases 
and importins or exportins have been detected. Shuttling of p38 across the nuclear membrane 
is most likely a result of specific interactions with NES- and NLS containing proteins, such 
as p38 activators, substrates or scaffold proteins (reviewed in Cyert, 2001 ). Finally, docking 
interactions can also regulate the subcellular localisation of MAP kinase and MAP kinase 
substrates. For example, p38 can form a stable complex with its substrate, MAPKAP-2, which 
contains a NLS sequence that permits the translocation of the MAPKAP-p38 complex from the 
nucleus (Ben-Levy et al., 1998). 
Protein phosphatases 
Inactivation of p38 occurs rapidly by dephosphorylation at either phospho-Thr180 or phospho-
Tyr182 by a family of protein phosphatases, called MAP kinase phosphatases (MKPs). MKPs 
are divided into three classes based on their preference for dephosphorylating tyrosine, 
serine/threonine or both tyrosine and threonine termed dual specificity phosphatases (DSPs) 
(reviewed in Keyse, 2000). Recently, there has been significant progress in understanding 
the regulation and role of DSPs (reviewed in Camps et at., 2000 and Farooq and Zhou, 
2004). In response to a specific stimulus, a subset of rapidly transcribed and translated DSPs 
translocates to a specific subcellular compartment within either the nucleus or cytoplasm. The 
DSPs become catalytically active upon binding via their amino-terminal domain to the target 
MAP kinase. If the bound MAP kinase is active, it will become rapidly dephosphorylated by the 
DSPs. However, if the MAP kinase is inactive, binding by the DSPs will prevent activation by 
any subsequent stimulus. 
Certain DSP family members display specificity for dephosphorylating different p38 isoforms. 
For example, whereas MAP kinase phosphatase-1 (MKP-1 ), MKP-4 and MKP-5 can efficiently 
dephosphorylate p38a and p38f3 (Chu et al., 1996; Muda et al., 1997; Tanoue et al., 1999), p38y 
and p385 are resistant to all MKP family members. Similarly, other types of phosphatases, such 
as the serine/threonine protein phosphatase type 2C (PP2C), have been shown to down regulate 
upstream activators of the p38 isoforms such as MKK6 and MKK4 both in vitro and in vivo 
{Takekawa et al., 1998). It is speculated that this may be a mechanism to differentially regulate 
the p38 isoforms in distinct tissue, cell and subcellular compartments. 
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1.5.2.3 Synthetic inhibitors of the p38 MAP kinase 
The p38 signalling pathway has been identified to play an important role in a number of 
inflammatory diseases such as rheumatoid arthritis, Alzheimer's disease and inflammatory 
bowel disease (reviewed in Westra and Limburg, 2006; Johnson and Bailey, 2003 and Peifer 
et al., 2006). During the inflammatory response, the p38 pathway is activated, leading to 
the production of proinflammatory cytokines and other proteins involved in mediating the 
inflammatory response (Lee et al., 1994; reviewed in Kyriakis and Avruch, 2001 ). Inhibition of 
the p38 pathway was therefore an obvious target for therapy of chronic inflammatory disease. 
The early inhibitors of p38 were pyridinyl imidazole compounds of which the most widely used 
is SB203580 and SB202190 (Badger et al., 1996; Lee at al., 1994 ). These inhibitors function 
by binding the active site of active and inactive forms of p38 thereby inhibiting the enzymatic 
activity of the kinase (Young et al., 1997; Frantz et al., 1998). Both SB203580 and SB202190 
are selective for p38a and p3813, and X-ray crystallography showed that Thr1 06 present in 
their ATP-binding domain is important for this selectivity (Tong et al., 1997; Kumar et al., 1997; 
Young et al., 1997; Lisnock et al., 1998). In addition to their therapeutic benefits, the SB203580 
and SB202190 inhibitors have also proven to be powerful experimental tools to distinguish 
between the roles of the p38 kinase and JNK in the stress response. 
1.5.2.4 DNA damage and the role of the p38 MAP kinase 
UV irradiation, a known mutagen and carcinogen, is a major causative agent in skin cancer 
because of its ability to induce DNA damage (reviewed in Cadet et al., 2005). The main 
mechanism of UV-induced DNA damage is the formation of DNA photoproducts, with the most 
common being pyrimidine dimers (CPD) and 6-4 photoproducts, which form at sites of adjacent 
pyrimidine bases. The intrastrand linkage between adjacent pyrimidines (usually thymidines), 
creates a distortion in the double helix thereby affecting replication and transcription. 
The DNA damage .induced by UV radiation triggers a distinct cellular response which involves 
activation of the DNA damage checkpoints and stress signalling pathways. A key player 
mediating the cells response to DNA damage is the tumour suppressor protein, p53. Once 
activated p53 can arrest the cells at G1 and G2 to allow for repair of the damaged DNA, but if 
the damage is irreparable, p53 may either induce the cells to senesce or undergo apoptosis. 
p53 triggers a G1 arrest by, in part, inducing the expression of the CDKi, p21 (el Deiry et al., 
1993) which binds and inhibits the activity of the G1 cyclin/Cdk complexes (Xiong et al., 1993; 
Harperet al., 1993, 1995; reviewed in Sherr and Roberts, 1999). In response to DNA damage, 
p21 can also block cell cycle progression by inducing a G1 and G2 arrest independent of 
p53 (reviewed in Giono and Manfredi, 2006). The key role of p21 in inducing a G1 arrest in 
response to DNA damage was illustrated in studies which have shown that MEFs deficient for 
p21 exhibit an impaired G1 arrest, and deletion of p21 in a colon cancer cell line ablated the 
G1 arrest in response to different DNA damaging agents (Brugarolas et al., 1995; Deng et al., 
1995; Waldman et al., 1995). 
In response to DNA damage, p53 also plays a role at the G2/M checkpoint where it is required 
for the maintenance rather than the initiation of the G2 arrest. For example, in response to 
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ionizing radiation, wild type p53 cells arrest in G2 whereas mutant p53 cells can initially arrest 
but eventually escape and enter mitosis (Bunz et al., 1998). During G2 p53 halts cell cycle 
progression by directly repressing the expression of the Cdc25c phosphatase (St. Clair et al., 
2004) and by upregulating the expression of 14-3-3a (Hermeking et al., 1997) which functions 
to sequester Cdc25c in the cytoplasm, preventing it from activating the cyclin B1/CDK1 (Dalal 
et al., 1999). A number of different mechanisms have been identified for the involvement of 
p21 in arresting cells in G2 in response to DNA damage. During late G2, in response to DNA 
damage p21 binds inactive cyclin A/Cdk2 and to a lesser extent cyclin B1/Cdk1 complexes and 
this interaction is thought to delay entry into mitosis (Dulic et al., 1998). Furthermore, when cells 
lacking either p53 or p21 are gamma-irradiated they enter mitosis but are unable to complete 
cytokinesis, and subsequently either exhibit features of chromosomal instability or undergo 
apoptosis (Bunz et al., 1998). Ando et al. (2001) has also shown that the interaction between 
p21 and the proliferating cell nuclear antigen (PCNA) is required to maintain this G2 arrest. 
They show that in the absence of DNA damage, PCNA associates with Cdc25C which results in 
the activation of cyclin B1/CDK1 and hence in promoting G2/M transition. In response to DNA 
damage, however, p21 was found to induce a G2 arrest by complexing with PCNA and thus 
blocking the association of PCNA with Cdc25C. Interestingly, the p21-PCNA complex further 
prevents G2/M transition by sequestering cyclin B1/CDK1 and holding it inactive. Consistent 
with the above study, Charrier-Savournin et al. (2004) showed using normal human fibroblast 
cells that in response to non-repairable DNA damage, p21 retains inactive cyclin B1/CDK1 
in the nucleus, thus preventing its activation and recruitment to the centrosomes. Moreover, 
p21 can also inhibit activation of the cyclin B1/Cdk1 complexes by preventing the CAK from 
activating the Cdk1 kinase (Smits et al., 2000). Taken together, p21 appears to mediate a G2 
cell cycle arrest through multiple mechanisms which ultimately involve inhibiting the activity of 
the cyclin/Cdks and/or PCNA. 
UV-induced p38 activation plays an important role in the p53-mediated cell cycle arrest 
described above. A number of studies have demonstrated that following UV radiation, p53 is 
multiply phosphorylated at serine residues by p38. In vitro and in vivo studies have shown that 
in response to UVB, mouse p53 is phosphorylated at serine 15 by ERK and p38 (She et al., 
2000). This phosphorylation was shown by Shieh et al. (1997) to prevent binding of MDM2 to 
p53 and thus to increase the stability of the protein. Furthermore, UVB irradiation of normal 
human keratinocytes led to phosphorylation of p53 at serine 15 by p38, which was found to 
protect these cells from apoptosis (Chouinard et al., 2002). Interestingly, in another study, p38 
was shown to phosphorylate human p53 at serine residues 33 and 46 in response to UVC 
radiation (Bulavin et al., 1999). Phosphorylation at these two sites was also shown to induce 
both the transcriptional activity of p53 as well as the ability of p53 to mediate apoptosis in 
response to UV radiation. Furthermore, phosphorylation by the p38 kinase at these two sites 
was also shown to be important for the subsequent phosphorylation of p53 at two other N-
terminal residues, serine 15 and 37, in response to UV radiation. UVC induced phosphorylation 
of p53 at serine 389 by p38 has also been observed. Phosphorylation at this site by the p38 
kinase is required for the regulation of the DNA-binding and transcriptional activity of p53 
(Keller et al., 1999; Huang et al., 1999). 
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Depending on the degree of damage, activation of the p38-p53 signalling cascade in response 
to UV radiation may be transient to allow repair of the damaged DNA or prolonged to promote 
apoptosis. The mechanism(s) controlling the duration of activation of the p38-p53 signalling 
cascade therefore needs to be tightly regulated. Recently, a novel p38 regulated protein, called 
p18Hamlet was identified as an important co-activator of p53 (Cuadrado et al., 2007). In response 
to UV, phosphorylation by the p38 MAP kinase leads to increased stability of p18Hamlet, which 
enhances its association with p53 to stimulate the transcription of several of its proapoptotic 
target genes, such as the p53 upregulated modulator of apoptosis (PUMA) and NOXA (Latin 
meaning "harm" or "damage"). A study by Takekawa et al. (2000) on the other hand, has 
described a mechanism which leads to the downregulation of the p38-p53 signalling pathway 
during the recovery period following UV radiation. They show that the Wip1 phosphatase 
dephosphorylates and consequently inactivates p38, which selectively inhibits its ability to 
phosphorylate p53 thereby suppressing both p53-mediated transcription and apoptosis in 
response to UV radiation. 
The p38 signalling pathway has also been shown to play a role at the G2 checkpoint in 
response to UV irradiation which is independent of p53 (Bulavin et al., 2001 ). The ability of p38 
to phosphorylate Cdc258 phosphatase was identified as one molecular mechanism for the 
UV-induced G2 arrest. In vitro, p38 was shown to bind and phosphorylate Cdc25B at serine 
309 (Bulavin et al., 2001) and serine 323 (Lindqvist et al., 2004 ), which results in it binding to 
the 14-3-3 proteins and thus preventing its translocation into the nucleus, where it is required 
to activate the cyclin 81/CDK1 complex (Bulavin et al., 2001 ). Interestingly, a recent study 
by Manke et al. (2005) identified a different mechanism for the G2/M arrest in response to 
UVC irradiation. This mechanism involves the downstream substrate of p38, MAPKAP K2. In 
response to UV-induced damage MAPKAP K2 induces cell cycle arrest by phosphorylating 
Cdc25B and C which induces binding of 14-3-3. They show using RNAi that endogenous 
MAPKAP K2 is responsible for inducing not only G2 but also the G1 and S checkpoints in 
response to UV irradiation (Manke et al., 2005). The investigators of this study argue that as 
p38 requires MAPKAP K2 to translocate from the nucleus (Ben-Levy et al., 1998) and since the 
experiments by Bulavin et al. (2001) involved immunoprecipitating p38 from the nucleus, they 
may have overlooked the presence of MAPKAP K2 in their immunoprecipitates. 
1.6 General and specific aims of study 
During development, Tbx2 has been implicated in several processes such as coordinating cell 
fate, patterning and morphogenesis of a wide range of tissues and organs. Furthermore, Tbx2 
is also emerging as a key regulator of the cell cycle and dosage sensitivity of this gene has 
been implicated in several cancers. However very little is also known about the biochemical 
pathways regulating the expression and activity of Tbx2, and while its role as a transcriptional 
repressor is well defined there is limited information regarding its target genes. The identification 
of kinases and signalling pathways regulating the activity of Tbx2 is imperative in order to 
elucidate the precise role of Tbx2 in the cell cycle, which may shed light on its oncogenic role. 
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Preliminary work in our laboratory, in collaboration with Dr Colin Goding (Marie Curie Research 
Institute, UK), has previously shown that TbX2 is phosphorylated by the p38 MAP kinase and 
the mitotic cyclin/Cdk complexes. 
The specific aims of this study were: 
1. to determine whether Tbx2 is phosphorylated by the p38 MAP kinase, cyclin A/Cdk2 and 
cyclin B1/Cdk1 both in vitro and in vivo 
2. to map the specific sites within Tbx2 targeted by p38 MAP kinase, cyclin A/Cdk2 and cyclin 
B1/Cdk1 
3. to determine the functional consequence of Tbx2 phosphorylation by the identified kinases 
by testing the affect of phosphorylation on: 
(a) the protein stability of Tbx2 
(b) the subcellular localisation of Tbx2 
(c) the ability of Tbx2 to repress transcription of the p21 gene 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Plasmids and DNA constructs 
All constructs used in this study were prepared according to standard techniques (Sambrook 
et al., 1989, pp 1.25-1.51). The wild-type (WT} p21-luciferase (LUC) construct contains a 2.2 
kb Sac 1- Hind Ill fragment of the human p21 promoter inserted upstream of a LUC reporter 
gene (el Deiry et al., 1993). As has previously been described the pCMV19.Tbx2 and pGEX. 
Tbx2 were constructed by cloning a full-length Bam HI fragment of the mouse Tbx2 eDNA 
into the Bam HI site of the pCMV19a and pGEX.2TK vectors, respectively (Carreira et al., 
1998). The GST-cyclin A and 81 fusion constructs and T7-plink Tbx2 full-length and deletion 
constructs were kindly provided by Dr C. Goding (Marie Curie Research Institute, UK). The 
pGL3-Basic-p14ARF (642) luciferase construct was kindly provided by Dr D. Holzschu (Ohio 
University, Athens, Ohio). 
WT Tbx2 and Tbx2 point mutants were cloned as Bam HI fragments into the polylinker of 
the pGEX.2TK expression vector 3' to the GST. Briefly, 10 IJg pCMV19.Tbx2 was digested 
with 0.5 units/IJI Bam HI (Roche, Switzerland) at 37°C for 3 hours (hr}. The DNA was then 
precipitated overnight in 3M NaOAc (1/10 volume) and 100% ice-cold ethanol (2.5X) at -20°C. 
The DNA was collected by centrifugation at 14 000 rpm for 15 min at room temperature (RT) 
and the pellet air-dried and resuspended in 30 IJI dH20. The DNA was electrophoresed on a 
0.8% agarose gel and the Bam HI fragment of the full-length Tbx2 was directly purified from 
the agarose gel using the Wizard SV Gel and PCR Clean-Up System kit (Promega, USA) 
according to the manufacturer's instructions. 
To generate the N-terminal (1-371 amino acids) Tbx2 protein, the Bg/11-Eco Rl Tbx2 eDNA 
fragment (1140-2281 bp) was released from the pGEX. Tbx2 plasmid with appropriate enzymes. 
To ensure efficient religation of the remaining plasmid, the blunt-ended Bg/11 and Eco Rl digested · 
plasmid was incubated with 0.5 units/IJI MuLV reverse transcriptase (Applied Biosystems, CA, 
USA) for 30 min at 37°C. The plasmid was precipitated overnight by adding 200 IJI dH20, 3 M 
NaOAc (1/10 volume) and 100% ice-cold ethanol (2.5X) at -20°C. To generate the C-terminal 
(371-711 amino-acids) Tbx2 protein, the Tbx2 eDNA fragment (1140-2281 bp) was subcloned 
as a Bg/11-Eco Rl fragment into the pGEX.2TK expression vector. 
2.2 Site-directed mutagenesis of the mouse Tbx2 eDNA 
Point mutations were introduced into the pCMV19.Tbx2 expression construct containing the 
full-length WT Tbx2 eDNA by site-directed mutagenesis using the Stratagene QuikChange 
system (California, USA) and appropriate primer pairs containing the desired mutations (see 
Table 2.1 ). Standard polymerase chain reaction (PCR) mix contained: 1X Reaction buffer, 
25 ng ds DNA template, 125 ng Forward primer, 125 ng Reverse primer, 1 IJI dNTP mix, 4 IJI 
Dimethyl Sulphoxide (DMSO) (Sigma, St. Louis, MO, USA), 1 IJI PfuTurbo DNA polymerase (2.5 
U/IJI) in a total volume of 50 IJI. The parameters for PCR amplification were 30 seconds (sec) 
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Table 2.1. Sequence of primers used to generate mutant Tbx2 eDNA constructs by site-directed 
mutagenesis• 
Mutant generated Mutation ds DNA template Forward pnmer RE site 
ontroduced 
S192A S192A WT Tbx2 5'-CATCCACCCGGACgctCCGGCC8.C.C.G.G.IGAACAGTGGATG-3' Age I 
S192E S192E WTTbx2 5'-CATCCACCCGGACgagCCGGCC~GAACAGTGGATG-3' Agel 
S336A S336A WTTbx2 5'-GAACCACCGCCCgccCCCAGCGCTGCGCCCAGCCCC-3' Eco47111 
S336E S336E WTTbx2 5'-GAACCACCGCCCgagCCC~GCGCCCAGCCCC-3' Eco47111 
S192A:S336A S336A S192A 5'-GAACCACCGCCCgccCCCAGCGCTGCGCCCAGCCCC-3' Eco47 111 
S192E:S336E S336E S192E 5'-GAACCACCGCCCgagCCC~GCGCCCAGCCCC-3' Eco47111 
S342A S342A WTTbx2 5'-CCCTCCCCC~GCGCCCgccCCTCTGCGCCTAC-3 ' Eco47111 
S342E S342E WT Tbx2 5' -CCCTCCCCC~GCGCCCgagCCTCTGCGCCTAC-3 ' Eco47111 
S336A:S342A S336A:S342A WTTbx2 5'-GAACCACCGCCCgccCCC~GCGCCCgccCCTCTGCGCC-3 ' Eco47111 
S336E:S342E S336E:S342E WTTbx2 5'-GAACCACCGCCCgagCCC~GCGCCCgagCCTCTGCGCC-3' Eco47111 
S623A S623A WTTbx2 5'-GGGCAGTGCC~CGTCTGCGCTTCgctCCTTACCAG-3' Stu I 
S623E S623E WTTbx2 5'-GGGCAGTGCC~CGTCTGCGCTTCgagCCTTACCAG-3' Stu I 
S675A S675A WTTbx2 5'-CGCGGGGCCCTAgcgCCC~TCAGCCAAAG-3' BspEI 
S675E S675E WTTbx2 5'-CGCGGGGCCCTAgagCCC~ TCAGCCAAAG-3' BspEI 
S336A:S623A:S675A S336A S623A:S675A 5'-GAACCACCGCCCgccCCC~GCGCCCAGCCCC-3' Eco47 111 
S336E:S623E:S675E S336E S623E:S675E 5'-GAACCACCGCCCgagCCC~GCGCCCAGCCCC-3' Eco47111 
•Primer sequences corresponding to the template Tbx2 eDNA are represented in uppercase. Mutations converting serine to either alanine (GCC, GCT or GCG) or glutamic 
acid (GAG) are depleted in bold lower case. Restriction enzyme sites introduced via the mutation are underlined with the point mutation in bold. Mutants generated in the 
present study are highlighted in blue font 
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at 95°C for 1 cycle, 30 sec at 95°C, 1 minute (min) at 55°C and 12 min at 68°C for 16 cycles. 
PCR was performed on a Hybaid PCR Express Thermal cycler (Middlesex, UK). The PCR 
products were assessed by agarose gel electrophoresis to confirm successful amplification. 
The synthesised DNA containing the mutation was selected for by digesting the methylated, 
non-mutated parental DNA template with 1 IJI Dpn I (10U/1JI) endonuclease for 1 hr at 37°C. 
XL 1-Biue supercompetent cells (Stratagene, USA) were transformed with 1 IJI of the Dpn I 
digested DNA as follows: incubation on ice for 30 min, heat pulsing at 42°C for 45 sec and 
ice treatment for 2 min. To each transformation reaction 0.5 ml of NZY+ broth (see Appendix), 
preheated to 42°C, was added and then incubated for 1 hr at 37°C with shaking at 225-250 
rpm. Following incubation, the entire volume of each transformation reaction was plated onto 
Luria broth Ampicillin (50 IJg/ml) agar plates. Plates were incubated at 37°C for at least 16 
hrs. To confirm successful transformation of the mutated plasmid DNA, the presence of the 
mutation was verified by restriction enzyme analysis (see Table 2.1) and sequencing. 
2.3 Cell culture 
2.3.1 Maintenance of cells in culture 
COS-7 monkey kidney cells, NIH 3T3 mouse fibroblasts, Wl-38 human lung fibroblasts, 
HT1080 human fibrosarcoma cells, B1Tbx2 mouse 3T3 fibroblast cells stably expressing SV-
5 tagged Tbx2 and the CT-1 transformed human lung fibroblast cell line stably expressing 
TBX2 (CT-Tbx2, Davis et al., 2007) were grown in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), 200 units/ml penicillin and 100 
IJg/ml streptomycin. Mouse 816 melanoma cells were grown in RPMI1640 supplemented with 
10% FBS, 200 units/ml penicillin and 100 IJg/ml streptomycin and the MCF-7 human breast 
epithelial adenocarcinoma cell line, was cultured in RPMI1640 supplemented with 10% FBS, 
1 mM sodium pyruvate, 0.1 mM MEM non-essential amino acids and 0.01 mg/ml insulin. Cells 
were maintained in a 37°C incubator (95.0% air/5% C02, 65% humidity) and cell media were 
replaced every 2-3 days. All cultures were routinely subjected to mycoplasma tests and only 
mycoplasma free cells were used in experiments. 
2.3.2 Mycoplasma test 
Cells grown on a coverslip in antibiotic-free media for 2-3 days were fixed in a 1 :3 mixture 
of glacial acetic acid and methanol for 5 sec, washed briefly with water to remove the fixing 
solution and then air-dried at RT for 5 min. Once dried, the DNA was stained with Hoechst 33258 
(0.5 IJg/ml) for 30 sec, washed briefly with water to remove excess stain and then mounted 
on a slide with mounting fluid (see Appendix) at pH 5.5. The cells were viewed immediately 
by fluorescence microscopy under the DAPI filter. Mycoplasma negative cells stained positive 
with Hoechst 33258 only in the nucleus, while cells infected with mycoplasma showed staining 
in both the nucleus and cytoplasm. 
35 
2.4.5 Phosphatase treatment 
Prior to SDS~Polyacrylamide Gel Electrophoresis (PAGE), 30 IJg MCF-7 whole celllysates were 
either incubated in the presence of one unit of shrimp alkaline phosphatase (USB, Cleveland, 
OH, USA) at 37°C for 30 min or were not treated with phosphatase. The reaction was stopped 
by adding 5X SDS loading buffer (see Appendix) and boiled at 1 00°C for 5 min. 
2.5 Transfection assays 
Prior to performing transfections, the concentration and quality of all DNA constructs was 
confirmed by agarose gel electrophoresis (data not shown). COS-7 and NIH 3T3 cells were 
transiently transfected with FuGENE 6 (Roche, Switzerland) and/or FuGENE HD (Roche, 
Switzerland) using a 3:1 ratio according to the manufacturer's instructions. Cells were plated 
at 0.5 X 1 05/ml in 35 mm dishes 1 day before transfection. Three microlitres of the transfection 
reagent diluted into 97 IJI serum-free media (without antibiotic) was prepared at RT and allowed 
to stand for 5 min. The diluted transfection reagent was added in a dropwise manner to the. 
DNA, mixed and incubated at RT for 15 min. Next the transfection reagent: DNA complex was 
added dropwise to the cells and thereafter incubated for thirty hours in a 37°C incubator. COS-
7 and NIH 3T3 cells were transfected with 0.5 IJg and 1 1-1g DNA, respectively. 
2.6 Luciferase assays 
COS-7 cells were transfected with 700 ng of the p21 or p14ARF luciferase reporter plasmid plus 
200 ng of the Tbx2 expression plasmid or 200 ng of an empty vector plasmid (pCMV19). The 
vector pRL-TK, containing the thymidine kinase promoter which drives the expression of a renilla 
reporter, was used as an internal control for transfection efficiency (50 ng per transfection). 
Cells were cultured for 30 hr and extracts were then assayed for firefly and renilla luciferase 
activity using the dualluciferase assay system (Promega, Madison, WI, USA) according to the 
manufacturer's instructions. Briefly, cells cultured in a 35 mm dish were lysed using 1 X lysis 
buffer. Cell lysates subjected to two freeze-thaw cycles were collected by centrifugation at 13 
000 rpm for 1 min at RT. The supernatant was transferred to a fresh eppendorf and 10 1-11 of cell 
lysate was assayed immediately for reporter gene activity. Luciferase activities were measured 
using the Luminoskan Ascent luminometer (Thermo Labsystems, Franklin, MA, USA). To 
normalise transfection efficiency, firefly luciferase values were divided by the renilla luciferase 
activity. Promoter activity was calculated as a ratio of the luciferase activity generated by the 
empty vector (without Tbx2) to that obtained in the presence of the appropriate expression 
vector. All luciferase assays were performed in duplicate and at least three independent 
experiments were done to confirm reproducibility. The Microsoft Excel programme was used 
to calculate the standard deviation and statistically significant differences between samples 
using the Student t test. P values of <0.05 were considered statistically relevant. 
2.7 Western blot analyses 
Cells were harvested by trypsinisation, washed twice with ice-cold PBS and collected by 
scraping with a 1 ml plunger. Whole cell extracts prepared from cells using RIPA buffer (see 
37 
Appendix) were stored on ice for 30 min and collected by centrifugation at 12 000 rpm for 20 min 
at 4°C. The protein concentration for each cell extract was determined using the BCA Protein 
Assay kit (Pierce, USA), with bovine serum albumin as the standard. Equal amounts of protein 
were loaded in each lane and resolved on 7.5-15% SDS-PAGE gels and then transferred 
electrophorectically to a Hybond ECL nitrocellulose membrane (Amersham Biosciences, 
USA). Following exposure to blocking solution (see Appendix) for 1 hr at RT with shaking, the 
membrane was incubated with the appropriate primary antibodies overnight at 4°C. Following 
this, the membrane was incubated with either goat anti-mouse or goat anti-rabbit lgG (H+L)-
HRP conjugated secondary antibodies (1 :5000) (BioRad, Hercules, CA, USA) at RT with 
shaking for 1 hr. Proteins of interest were detected using the SuperSignal Chemiluminiscent 
system (Pierce, USA). Primary antibodies and appropriate dilutions were: mouse monoclonal 
anti-Tbx2 62-2 antibody (1 :2000), rabbit polyclonal anti-phospho-p38 (1 :1000) (Cell Signaling 
Technology Inc., Beverly, MA), rabbit anti-p38 (1 :5000) (Sigma, Missouri, USA), anti-Pk-Tag 
(SV5) antibody (1 :3000) (Serotec, Oxford, UK) and rabbit polyclonal anti-p21 (1 :200), anti-
cyclin A (1: 1 000), anti-cyclin B1 (1 :1000) and mouse monoclonal anti-a-tubulin (1 :500) all from 
Santa Cruz Biotechnology, CA, USA. 
2.8 Immunofluorescence 
Cells, grown on coverslips in 35mm dishes were washed with PBS and then fixed with 4% 
paraformaldehyde for 20 min at RT. Thereafter the cells were permeabilised in 0.2% Triton 
X-100/PBS at RT for 10 min. Following permeabilisation, cells were blocked for 1hr in 5% 
swine serum in PBS at RT. After overnight incubation at 4°C with the appropriate antibodies 
(diluted in PBS and 5% swine serum), cells were washed and incubated with the appropriate 
fluor-conjugated secondary antibodies (1 :1000 dilution) for 90 min in the dark at RT. For DNA 
staining, cells were incubated with 1 ~g/ml DAPI (4',6-diamidino-2-phenylindole) (Sigma, 
Germany) diluted in PBS for 10 min at RT in the dark. Cells were washed and then mounted 
on slides with Mowial mounting medium (Hoechst, Germany) containing Anti-Fade (Sigma, 
USA). Fluorescent cells were viewed using standard FITC and DAPI filters on an Axiovert 
fluorescent microscope (Zeiss, USA). Primary antibodies (have been described in 2. 7): anti- · 
Tbx2 antibody (1 :750), anti-phospho-p38 (1: 1 000) and rabbit polyclonal anti-phospho-Histone 
H3 (1 :200) (Upstate Biotechnology, Charlottesville, USA). Secondary antibodies used were: 
alexa 488 goat anti-mouse (Molecular Probes, Eugene, USA) and Cy3 donkey anti-rabbit lgG 
(Jackson lmmunoResearch Laboratories, Inc., USA). Negative controls had primary antibody 
excluded. 
2.9 Bacterial expression and purification of glutathione S-transferase (GSTl 
fusion proteins 
All GST-fusion proteins were prepared in the pGEX.2TK vector as previously described (see 
2.1 ). The GST-fusion proteins were transformed into the Escherichia coli (E. colt) strain plysS 
and protein expression induced for4 hrwith 0.5 M isopropyl-1-thio-D-galactopyranoside (IPTG) 
(Promega, USA) at 37°C with shaking. Bacterial cells were collected by centrifugation at 3 000 
rpm for 30 min at RT and the resulting pellet resuspended in 1 ml PBSTi buffer (see Appendix) 
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was lysed by sonication. Cellular debris was removed by centrifugation at 13 000 rpm for 30 
min at 4°C. The protein lysates were incubated with 140 1-JI/PBSTi Glutathione Sepharose 4B 
beads (Amersham Biosciences, USA) for 1 hr at 4°C with rolling. The bead-bound complexes 
were washed four times in 1 ml PBSTi buffer. Following washes, the purified proteins were 
resuspended in 200 1-11 PBSTi and stored at 4°C. Quantification was accomplished by resolving 
equal volumes of GST and GST-fusion protein on a 12% SDS-PAGE followed by Coomassie 
staining. 
2.10 In vitro kinase assay 
Kinase assays were performed using 25 ng recombinant active p38a protein kinase (Upstate 
Biotechnology, Charlottesville, USA), 0.2 units/IJI recombinant cyclin A-CDK2 and cyclin B-
cdc2 (New England Biolabs, UK) in a 40 1-11 reaction volume (see Appendix) at 30°C for 30 
min. Briefly, the appropriate kinase was added to Tbx2-recombinant protein, in the presence 
of [y-32P]ATP (see Appendix). Following the kinase reaction, 30 1-11 of Glutathione Sepharose 
4B beads (Amersham Biosciences, USA) equilibrated in kinase buffer, were added to each 
sample. The samples were washed five times with 1 ml of reaction buffer. Each reaction was 
terminated by adding 20 1-11 of 2X SDS loading buffer followed by boiling at 1 00°C for 10 min. 
Proteins were resolved on a 12% SDS-PAGE, stained with Coomassie and destained before 
being dried for autoradiography. 
2.11 In vitro transcribed translated binding assays 
All GST-fusion proteins were expressed in E.co/i and were purified as described previously 
(see 2.9). In vitro synthesised proteins were generated from T7 plasmids using the TNT quick 
coupled transcription-translation system (Promega, USA). One microgram of desired DNA was 
transcribed and translated at 30°C for 90 min (see Appendix). For the positive control, 2 1-11 of the 
reaction mix was added to 3 1-11 dH
2
0 and 5 1-11 2X SDS loading buffer, mixed and heated at 1 00°C 
for 10 min. The GST-pulldown assays were performed by incubating equal amounts of GST 
or GST-fusion protein with Glutathione Sepharose 4B beads (Amersham Biosciences, USA) 
equilibrated in PBSTi buffer, 0.05 mg/ml bovine serum albumin and 10 1-11 of in vitro generated 
[
35S]-Iabeled protein. The mixture was incubated at 4°Cfor 90 min with rolling. Following rolling, 
the mixture was washed six times in 1 ml PBSTi buffer. After the final wash, the proteins were 
resuspended in 20 1-11 2X SDS loading buffer, boiled for 10 min at 1 00°C and resolved on a 12% 
SDS-PAGE. Protein-protein interaction was visualised by autoradiography. 
2.12 GST-pulldown assays 
Cell extracts enriched forcyclinAand cyclin B1 were obtained by lysing cells synchronised in G2 
(described in 2.4.2) in RIPA 150 mM NaCI buffer (see Appendix). Cellular debris was removed 
by centrifugation at 12 000 rpm for 30 min at 4°C. The supernatant of each sample was added 
to 200 1-11 of Glutathione Sepharose 4B beads (Amersham Biosciences, USA) equilibrated in 
RIPA and incubated for 2 hr at 4°C with rolling. Pre-cleared cell lysates were incubated with 
equal amounts of GST or GST-Tbx2 fusion proteins for 3 hr at 4°C with rolling. Protein-protein 
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complexes were pelleted by centrifugation at 6 000 rpm for 1 0 sec at RT and washed five times 
with 1 ml RIPA buffer. After the final wash, the protein complexes were resuspended in 30 IJI2X 
SDS loading buffer, boiled for 10 min at 1 00°C and resolved on a 12% SDS-PAGE for western 
blot analyses with antibodies to cyclin A (1 :1000) and cyclin 81 (1 :1000). 
2.13 Quantitative reverse transcription PCR (gRT-PCR) 
Total RNA was extracted from MCF-7 cells using the RNeasy Plus Mini kit (Qiagen, USA). 
The quality and concentration of RNA was determined by spectrophotometry. Only samples 
exhibiting a A26cfA280 ratio equal to or above 1.8 were selected and stored at -80°C for further 
applications. Reverse transcription of RNA was performed in a final volume of 20 !JI containing: 
4 !JI 5X Quantiscript RT buffer, 1 !JI Quantiscript Reverse Transcriptase, 1 !JI RT Primer mix, 
14 !JI RNA template (1 !Jg) (QuantiTect Reverse Transcription kit, Qiagen, USA). The samples 
were incubated at 42°C for 15 min and the reverse transcriptase inactivated by heating at 95°C 
for 3 min. Hereafter samples were prepared by real-time PCR. PCR mastermix was prepared 
as follows: 6 !JI RNase-free water, 2 !JI 1 OX QuantiTect primer assay, 10 !JI 2X QuantiTect 
SYBR Green PCR master mix (Qiagen, USA). Eighteen microlitres of PCR mastermix and 
2 !JI of eDNA were added to glass capillaries. The capillaries were sealed, centrifuged at 3 
000 rpm for 30 sec and placed in the LightCycler Version 3 (Roche, Switzerland). PCR cycle 
parameters were: denaturation (15 min at 95°C), annealing and amplification at 35 cycles (15 
sec at 94°C; 20 sec at 55°C; 20 sec at 72°C), melting temperature (15 sec at 65°C) and a 
cooling step (30 sec at 40°C). Each DNA sample was quantified in duplicate and a negative 
control without eDNA template was run with every assay to assess the overall specificity. The 
change in expression was calculated by the I).I).Ct method (see Appendix). Relative mRNA 
expression levels were normalised to GAPDHforeach reaction. Primers used to amplify human 
TBX2 (QT00091266) and p21 (QT00062090) were from Qiagen, USA. GAPDH: forward 5'-
GAAGGCTGGGGCTCATTT-3'; reverse 5'-CAGGAGGCATTGCTGATGAT-3'). The Microsoft 
Excel programme was used to calculate the standard deviation and statistically significant 
differences between samples using the Student t test. P values of <0.05 were considered 
statistically relevant. 
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CHAPTER 3: RESULTS 
As reviewed in section 1.3.2 significant progress has been made in elucidating the signalling 
pathways that regulate the role of Tbx2 in development. There has also been compelling 
evidence implicating Tbx2 in the regulation of the cell cycle and altered expression of this 
gene has been associated with several cancers (see section 1.3.3). However, very little is 
known about how the levels and function of Tbx2 are regulated during the cell cycle and 
tumourigenesis. This study has therefore focused on identifying signal transduction pathways 
and kinases that regulate the activity of Tbx2. The stress-responsive p38 signalling pathway 
and the mitotic cyclin A/Cdk2 and cyclin B1/Cdk1 were identified as direct regulators of Tbx2. 
Results are described below. 
3.1 TBX2 is a target for the stress-responsive DNA damage pathway 
3.1.1 In vivo phosphorylation of TBX2 
In order to determine whether TBX2 is regulated post-translationally by phosphorylation, protein 
extracted from MCF-7 cells, containing endogenous TBX2, was dephosphorylated with shrimp 
alkaline phosphatase and subsequently subjected to western blot analyses. Figure 3.1a shows 
that in contrast to the two bands seen in the untreated sample, only a single intense band was 
present in the phosphatase treated sample. These results suggest that the top band seen in 
the untreated sample represents phosphorylated TBX2 and that the protein is phosphorylated 
in vivo. 
When the human and mouse TBX2/Tbx2* sequences were examined for potential 
phosphorylation sites, using an online motif database (http://au.expasy.org/tools/scanprosite/), 
thirteen serine-proline (SP) motifs were identified (Fig. 3.1 b). Importantly these sites are 
conserved between the mouse and human proteins with one SP motif located within the T-box 
(see Fig. 1.1 ). These motifs are putative target sites for phosphorylation by several kinases, 
including members of the MAP kinase family (reviewed in Robinson and Cobb, 1997) and the 
cyclin dependent kinases (Holmes and Solomon, 1996), suggesting that the activity of TBX2/ 
Tbx2 may be regulated by phosphorylation at these sites. Since TBX2 was previously shown 
to act as an anti-senescence factor with a role in the cell cycle, we speculated that it may be 
phosphorylated and regulated by kinases involved in stress-induced signalling pathways and 
the cell cycle. 
3.1.2 Transfected Tbx2 is phosphorylated by p38 kinase in response to UVC 
irradiation 
To determine whether Tbx2 is a target for a stress-responsive kinase(s), the phosphorylation 
status of Tbx2 in response to UVC irradiation was investigated. COS-7 cells, 
* The accepted convention will be used for human (TBX2) and mouse (Tbx2), and when referring to 
both human and mouse, TBX2/Tbx2 will be used. 
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Figure 3.1. TBX2 is phosphorylated in vivo. (a) Dephosphorylation of TBX2 by shrimp alkaline 
phosphatase. Protein extracts (30 !Jg) from MCF-7 cells were dephosphorylated by incubation 
with 1 unit of shrimp alkaline phosphatase and were separated by 7.5% SDS-PAGE, for optimal 
separation of phosphorylated TBX2. Western blotting was performed with an antibody to Tbx2 
and tubulin was included as a loading control. p-TBX2 is phosphorylated TBX2. (b) Schematic 
representation of the human and mouse Tbx2 protein showing the position of all serine-proline 
(SP) motifs that are potential phosphorylation sites. The position of the DNA-binding domain, 
T-box, is shown. The amino acid sequence of human TBX2 (accession no. NP _005985) and 
mouse Tbx2 (accession no. NP _033350) were obtained from the protein database of the 
National Centre for Biotechnology Information (NCBI) . 
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that lack endogenous Tbx2, were transfected with a Tbx2 expression vector, exposed to 
increasing doses of UVC irradiation and protein extracts analysed by western blotting. Figure 
3.2a shows that with increasing doses of UVC irradiation there is an increase in phosphorylated 
Tbx2 from 10 J/m2 • This observed increase in phosphorylated Tbx2 is consistent with the 
appearance of activated p38, as detected using an antibody specific for phosphorylated p38. 
These results were confirmed by densitometric scanning of autoradiographs and the results 
are represented in the bar graph shown in the lower panel of Figure 3.2a. 
In response to a variety of cellular stresses, including UV irradiation, the JNK and p38 MAP 
kinase are strongly activated (reviewed in Kyriakis and Avruch, 2001 ). To identify which of these 
two kinases are responsible for Tbx2 phosphorylation, the above experiment was repeated in 
the presence of 88203580, which specifically inhibits p38, while being ineffective against JNK. 
In this experiment transfected COS-7 cells were exposed to a dose of 40 J/m2 UVC because 
it consistently yielded high levels of phosphorylated Tbx2 in many different experiments. Tbx2 
was detected as a single band (Fig. 3.2b) because the protein samples were analysed on a 
10% SDS-PAGE in this experiment, which does not allow resolution of phosphorylated Tbx2. 
On close inspection it is apparent that the band in the UVC irradiated cells migrates higher 
than that in the mock irradiated cells confirming that transfected Tbx2 is phosphorylated in cells 
exposed to UVC. In the presence of 88203580, however, the UVC-dependent phosphorylation 
of Tbx2 is partially inhibited as the protein migrates higher than the mock irradiated but lower 
than the UVC irradiated samples. A possible explanation for this partial inhibition is that the 
inhibitor did not completely abolish the activity of the p38 kinase since a faint signal was 
obtained for the active form of p38. Furthermore, activation of the p38 pathway was confirmed 
by the presence of phosphorylated p38 in the UVC irradiated cells only, which was inhibited by 
88203580. These results showed that the transfected Tbx2 protein was phosphorylated by the 
stress-responsive p38 kinase in response to UVC irradiation. 
3.1.3 Endogenous TBX2 is phosphorylated by p38 kinase in response to UVC 
irradiation 
Since the above experiments were done on cells expressing exogenously introduced Tbx2, it 
was important to determine whether UVC had the same effect on endogenous Tbx2. MCF-7 
breast cancer cells that overexpress T8X2 were thus exposed to a fixed dose of 100 J/m2 UVC, 
and protein harvested at various time points post-treatment was analysed by western blotting. 
The dose of UVC selected in this experiment was based on previous results, which showed 
that it consistently yielded high levels of phosphorylated T8X2 in MCF-7 cells. Figure 3.3a 
shows an increase in the phosphorylation status of T8X2 immediately after UVC irradiation 
(0 min) with high levels persisting up to 180 min post-treatment. It is interesting to note that 
the lower T8X2 band is also more intense immediately post-UVC treatment and is markedly 
elevated by 10 min. This would suggest that the effect seen on the lower band at these early 
time points is also due to post-translational modifications, such as acetylation, rather than 
due to increased mRNA levels. Activation of the p38 pathway was only observed in the UVC 





41 -as 41 ... -c: 5 10 20 40 80 UVC (J/m2) :::> 
I l-p-Tbx2 -Tbx2 
I I p-p38 




~ : : lli•Upperband 
" 1 
~ ~: Mll .!!.. 0.4 
0.2 
0 
UT 5 10 20 40 80 J/m2 
WTTbx2 







Figure 3.2. UVC-induced phosphorylation of transfected Tbx2 by p38 kinase. (a) Dose-
dependent increase in the phosphorylation status of transfected Tbx2 in response to UVC 
irradiation. COS-7 cells were transfected with a vector expressing SV5 epitope-tagged Tbx2 
and UVC irradiated at the indicated dosages. Protein extracts (3 IJg) were prepared 60 min 
post treatment. In order to detect phosphorylated Tbx2, protein samples were analysed on a 
7.5% SDS-PAGE and by western blotting using an antibody to SV5. Levels of phospho-p38 
and total p38 in these samples were assessed on a 12% SDS-PAGE and by western blotting. 
The bar graph compares the intensity of the upper (p-Tbx2) and lower (Tbx2) bands to the p38 
loading control for each sample. (b) Stress-induced phosphorylation of Tbx2 is inhibited in the 
presence of the p38 inhibitor. COS-7 cells were pretreated with 10 IJM 88203580, 30 min prior 
to 40 J/m2 UVC irradiation. To accurately detect Tbx2 as a single band an equal amount of 
protein from each sample was analysed by 10% SDS-PAGE with an antibody to SV5. Levels 
of phospho-p38 and total p38 were detected using the appropriate antibodies. 
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Figure 3.3. Endogenous TBX2 is phosphorylated in response to UVC by p38 kinase. (a) Time-
dependent increase in the phosphorylation of endogenous TBX2 in response to UVC irradiation. 
Protein extracts (441Jg) from MCF-7 cells at the indicated time points post-UVC irradiation (1 00 
J/m2 ) were separated by 7.5% SDS-PAGE and by western blotting to detect phosphorylated 
TBX2. Levels of phospho-p38 and total p38 in these samples were assessed on a 12% SDS-
PAGE and by western blotting with appropriate antibodies. The protein extracted from 0 to 30 
minutes and 60 to 300 minutes post-UVC treatment were from different experiments and were 
therefore analysed on separate gels. (b) Endogenous TBX2 is phosphorylated in vivo by p38 
kinase. MCF-7 cells irradiated with UVC (100 J/m2) in the presence or absence of SB203580 
(1 0 !JM , 30 min prior to UVC irradiation). Protein extracts (63 !Jg) were assayed as described 
in (a) above. (c) TBX2 mRNA levels increase in response to UVC irradiation. Quantitative real-
time PCR of endogenous TBX2 mRNA extracted from MCF-7 cells at the indicated times post-
UVC irradiation (100 J/m2) . The levels of TBX2 mRNA expression were normalised against 
GAPDH. Error bars represent means± standard deviation . 
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To confirm that this increase in phosphorylated TBX2 is due to activation of the p38 kinase, 
MCF-7 cells were exposed to UVC irradiation (100 J/m2) in the presence of SB203580. Based 
on the data represented in Fig. 3.3a, protein was harvested 60 min post-UVC irradiation and 
analysed by western blotting. Figure 3.3b shows that the UVC induced increase in endogenous 
TBX2 phosphorylation occurs specifically via the p38 MAP kinase as treatment with the p38 
inhibitor significantly reduces this effect. 
To determine the effect of UVC irradiation on TBX2 mRNA levels, quantitative real-time 
PCR was performed. RNA, extracted from MCF-7 cells at 0, 30 and 60 minutes post-UVC 
irradiation, was amplified using primers specific for TBX2. The TBX2 mRNA expression levels 
were normalised against the house keeping gene, GAPDH. Figure 3.3c shows that TBX2 
mRNA levels increased immediately post-UVC irradiation, peaking at 30 min. The mechanism 
by which UVC irradiation leads to an increase in TBX2 mRNA levels is discussed in Chapter 
4. Taken together, the results of the above experiments suggest that TBX2 protein levels 
increase in response to UVC irradiation due to both a phosphorylation dependent increase in 
the stability of the protein and an increase in mRNA levels. 
3.1.4 Tbx2 is phosphorylated at 5336, 5623 and 5675 by p38 kinase in vitro 
Having established that TBX2/Tbx2 is phosphorylated by p38 kinase in vivo, the next step was 
to identify these p38 target sites. SP and TP motifs are the minimum potential target sites for 
phosphorylation by the p38 kinase. The serine residues in the 13 candidate SP motifs within 
the Tbx2 protein were therefore individually mutated to alanine by site-directed mutagenesis 
(these were generated by Dr S. Prince) and tested in in vitro kinase assays. Briefly, the wild-
type (WT)- and mutant Tbx2 proteins were expressed as GST fusion proteins and used as 
substrates for the p38a kinase in the presence of [y-32P]ATP and the results visualised by 
autoradiography. In these kinase assays the GST-Tbx2 fusion proteins were expressed as 
either N-terminal (1-371) or C-terminal (371-711) proteins (Fig. 3.4a) as the full-length GST-
Tbx2 protein was found to be very unstable in these assays. 
The results (Fig. 3.4b) indicate that both the WT N- and C-terminal Tbx2 proteins were 
phosphorylated by the p38 kinase, which suggested that there were p38 target sites within 
both these portions of the protein. There are three SP motifs in the N-terminal Tbx2 protein and 
the S 192A and S342A mutants had no effect on phosphorylation. The S336A mutation however 
abolished phosphorylation of the N-terminal Tbx2 protein suggesting that it was the only p38 
target site in this part of the protein . In this experiment the S336A:S342A double mutant was 
included and results show that it behaved as the S336A mutant. The single mutations S623A 
and S675A reduced phosphorylation of the C-terminus of Tbx2 and when both these sites were 
mutated, phosphorylation was considerably reduced. Mutating the remaining eight potential 
p38 target sites in the C-terminus of Tbx2 had no effect on phosphorylation of the protein 
(data not shown). GST alone was used as a negative control. The lower panels in Figure 3.4b 
show the same gels stained with Coomassie Blue indicating that equivalent amounts of GST-
fusion proteins were used in these experiments. The bar graphs show densitometric values of 
radioactive levels measured for each construct used in the kinase assay. The results from these 
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Figure 3.4. Tbx2 is phosphorylated by p38 kinase at S336, S623 and S675 in vitro. (a) 
Schematic representation of theN-terminal (1-371) and C-terminal (371 -71 1) Tbx2 proteins 
used as substrates in p38 kinase assays. The sites mutated in constructs used in the kinase 
assays shown in (b) are indicated. (b) Mapping the p38 kinase target sites within Tbx2. In vitro 
p38 kinase assays were performed using purified GST-Tbx2 fusion proteins as substrates in 
the presence of the recombinant activated p38a kinase and [y-32P]ATP. The mutant GST-Tbx2 
fusion proteins were generated by site-directed mutagenesis as described in section 2.2 of 
the material and methods. Kinase assays using the indicated Tbx2 proteins are shown in the 
upper panel after 12% SDS-PAGE and autoradiography. The middle panel shows the same 
gels stained with Coomassie Blue indicating that equivalent amounts of protein were used 
in each assay. The bar graphs show densitometric values of radioactive levels measured for 
each construct in the kinase assay. (*) Refers to the 1-361 truncated Tbx2 protein. 
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assays identified S336, S623 and S675 as sites in the Tbx2 protein that were phosphorylated 
by the p38 kinase in vitro. 
3.1.5 Tbx2 is phosphorylated at 8336, 8623 and 8675 by p38 kinase in vivo 
response to UVC irradiation 
To determine whether the p38 target sites identified in the in vitro kinase assays are 
phosphorylated in vivo, a mutant was generated in which all three serine residues were 
mutated to alanine in the full-length Tbx2 protein (Tbx2 S336A:S623A:S675A). COS-7 cells 
were transfected with vectors expressing either SV5-tagged WT Tbx2 or a SV5-tagged Tbx2 
S336A:S623A:S675A mutant and their phosphorylation status compared by western blot 
analyses. Figure 3.5a shows that unlike WT Tbx2, the Tbx2 mutant is not phosphorylated and 
is expressed as a single band. These results suggest that serine residues 336, 623 and 675 
are indeed targets for in vivo phosphorylation. Given that mutating these three serine residues 
results in the complete loss of the upper phosphorylated band, would imply that they are critical 
for phosphorylation by an additional kinase(s). 
The next experiment investigated whether the identified serine residues were the only p38 
kinase target sites in response to UVC irradiation. To this end, cells were transfected with 
vectors expressing either SV5-tagged WTTbx2 or the SV5-tagged Tbx2 (S336A:S623A:S675A) 
mutant in the presence or absence of UVC and the Tbx2 phosphorylation status was compared 
(Fig. 3.5b ). In the untreated cells transfected with WT Tbx2, two bands were obtained although 
the intensity of the top band was much weaker in this experiment. As expected, the intensity of 
both WT Tbx2 bands increased in response to UVC irradiation. Mutating the serine residues 
336, 623 and 675, however, abolished this effect since only a single band was observed in 
both treated and untreated cells. Activation of the p38 pathway was only observed in the UVC 
treated cells and total p38 showed equal loading. These results confirmed that the identified 
sites were the only p38 targets for phosphorylation of Tbx2 in response to UVC. 
3.1.6 The TBX2 protein is regulated by p38 kinase phosphorylation 
Having established that TBX2 is phosphorylated by the p38 kinase in response to UVC-induced 
cellular stress, the question arose as to whether phosphorylation might regulate its protein 
stability and subcellular localisation? 
3.1.6.1 Pseudo-phosphorylation of the p38 target sites prevents Tbx2 degradation 
Previous results (see Fig. 3.3a) showed an increase in phosphorylated TBX2 immediately 
post-UVC treatment (0 min), which suggested that the stability of the protein was regulated by 
phosphorylation. To address this possibility the effect of p38 phosphorylation on Tbx2 protein 
stability was investigated. This was achieved by mutating the p38 target sites to alanine 
(A), to abolish phosphorylation or to glutamic acid (E), to mimic phosphorylation. NIH 3T3 
cells, transiently transfected with either WT Tbx2 or the Tbx2 mutants, were incubated with 
cycloheximide over a period of 6 hours and protein extracts were subjected to western blot 
analyses (Fig. 3.6). In order to accurately quantify total levels of Tbx2 in this experiment, cell 
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Figure 3.5. Tbx2 is phosphorylated at 8336, 8623 and 8675 in vivo. (a) Mutating the p38 
kinase sites affects the phosphorylation of Tbx2 in vivo. 8V5 epitope-tagged Wf Tbx2 or the 
8V5 epitope-tagged Tbx2 8336A:8623A:8675A mutant were expressed in C08-7 cells and 
an equal amount of protein from each sample was separated by 7.5% 808-PAGE and by 
western blotting to analyse the phosphorylation status of Tbx2 using an anti-8V5 antibody. 
p-Tbx2 is phosphorylated. (b) The serine residues 336, 623 and 675 in the Tbx2 protein are 
the only sites phosphorylated by p38 in response to UVC. Cells were transfected with the Tbx2 
constructs described in (a) and exposed to UVC (40 J/m2) 29 hrs post-transfection. Protein 
extracts were prepared 60 min post-UVC treatment and Tbx2 was detected as described in (a). 
Phospho-p38 and total p38 were run on a 12% 808-PAGE and assessed by western blotting 
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Figure 3.6. Pseudo-phosphorylation at the p38 target sites increases Tbx2 protein stability. 
NIH 3T3 cells transiently transfected with vectors expressing SV5 epitope-tagged Tbx2 proteins 
as indicated , were incubated 48 hr post-transfection with 30 IJg/ml cycloheximide (CHX) for 
the indicated times. To accurately detect total levels of the Tbx2 protein as a single band, an 
equal amount of protein from each sample was analysed on a 10% SDS-PAGE and by western 
blotting with anti-SV5 antibodies. The bar graph compares the intensity of Tbx2 normalised to 
the tubulin loading control. 
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Tbx2 S336A:S623A:S675A mutant protein was unstable with an approximate 30% decrease 
in protein levels at 6 hours. In contrast, the levels of the pseudo-phosphorylated Tbx2 S336E: 
S623E:S675E mutant remained unchanged throughout the treatment. In this experiment the 
WT Tbx2 protein increases slightly over the period of cycloheximide treatment and it is not clear 
whether this is of any significance as, in similar experiments, the protein mimics the levels of 
the pseudo-phosphorylated protein. The densitometric graph in the lower panel compares the 
intensity of the Tbx2 protein normalised to the tubulin loading control. This finding implicates 
the p38 kinase as a modulator of Tbx2 protein stability in response to cellular stress. 
It is important to note that in these experiments, NIH 3T3 fibroblasts were used because, 
compared to COS-7 cells they transfect less efficiently (20% vs 90%) and thus increase the 
chance of distinguishing small changes in the levels of transfected protein. Furthermore, the 
high transfection efficiency seen in COS-7 cells was expected to lead to the expression of high 
levels of the transfected protein, which may compromise the proteolytic machinery. 
3.1.6.2 UVC-induced phosphorylation of TBX2 by p38 kinase induces nuclear 
translocation of TBX2 
In the course of this study TBX2 was observed to be both cytoplasmic and nuclear in MCF-7 
cells by immunofluorescence. To establish whether phosphorylation by the p38 MAP kinase 
affected the subcellular localisation of TBX2, MCF-7 cells were mock irradiated (untreated) 
or UVC-irradiated in the presence or absence of the p38 inhibitor, 88203580. The cells were 
processed for immunofluorescence with an antibody to Tbx2 (Fig. 3.7). As expected, TBX2 
was found to exhibit diffuse staining both in the cytoplasm and nucleus of the untreated cells. 
In UVC-irradiated cells, however, TBX2 was predominantly localised in the nuclei and cells 
pre-treated with the p38 inhibitor have a similar staining pattern to that seen in untreated cells. 
These results are emphasised at high magnification (Fig. 3.7, lower panel) and indicate that 
phosphorylation of TBX2 by the p38 kinase in response to UVC irradiation results in the almost 
exclusive localisation of the protein to the nucleus. 
Taken together the above results showed that phosphorylation of TBX2 by the p38 kinase in 
response to UV-induced stress regulates TBX2 protein stability and subcellular localisation. 
3.1.7 UVC-induced phosphorylation by p38 enhances the ability of Tbx2 to repress 
p21 
The above results suggested that TBX2 may be playing a role in the UV stress pathway. 
Interestingly, it is well established that p21, a known Tbx2 target (Prince et al., 2004), is 
critical for mediating the cell cycle arrest required for DNA damage repair post-UV irradiation 
(reviewed in Fotedar et al., 2004). However, recent reports suggest that p21 inhibits DNA 
repair (Pan et al., 1995; Cooper et al., 1999; Bendjennat et al., 2003) and that subsequent to 
establishing a cell cycle arrest following UV irradiation, p21 has to be downregulated (McKay 
et al., 1998; Wang et al., 1999; Bendjennat et al., 2003). This UV-mediated downregulation of 
p21 was previously observed at both the protein and mRNA levels in MCF-7 cells (Wang et 
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Figure 3.7. p38 phosphorylation induces nuclear translocation of TBX2. MCF-7 cells were 
irradiated with UVC (100 J/m2 ) in the presence or absence of SB203580 and then analysed 60 
min post-treatment by immunofluorescence using an antibody to Tbx2. All cells were stained 
with DAPI, to determine the location of the nuclei. The upper and lower panels represent 
images captured at 40X and 1 OOX magnifications, respectively. 
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levels. This study tests this hypothesis by firstly investigating whether there was an inverse 
correlation between TBX2 and p21 protein levels in UVC irradiated MCF-7 cells (Fig. 3.8a). The 
results show that immediately post-UVC irradiation (0 min) there was a substantial increase 
in p21 levels followed by a decrease, which corresponded with increased TBX2 levels at all 
subsequent time points. It is important to point out that the protein extracted from the 0 to 30 
minutes and 60 to 300 minutes post-UVC treatment were from separate experiments and were 
therefore analysed on different gels. This may account for the difference in p21 protein levels 
seen in the untreated lanes of the two blots and thus does not detract from the interpretation of 
the results . Levels of p-p38 are included to show activation of the p38 pathway. 
To determine whether the decrease in p21 seen above was due to reduced levels of p21 
mRNA, quantitative real-time PCR was performed. Results (Fig. 3.8b) revealed that relative 
to the untreated cells p21 mRNA levels were down regulated immediately after UVC treatment 
and remained low over the period when TBX2 protein levels went up. The results of the above 
western blot and quantitative real-time PCR experiments thus reveal an inverse correlation 
between TBX2 protein and p21 mRNA levels in UVC irradiated MCF-7 cells. This suggests that 
TBX2 may be involved in the reduced levels of p21 seen under these conditions. 
The possibility that stress-induced phosphorylation by p38 kinase potentiates the ability of 
Tbx2 to repress transcription of the p21 gene, was next investigated. COS-7 cells were co-
transfected with a WT Tbx2 expression vector together with a p21 promoter-luciferase (LUC) 
reporter and the cells treated with or without UVC irradiation. Basal promoter activity was 
determined using the empty control vector (pCMV19.SV5). The results of three independent 
experiments in which each construct was tested in duplicate, are shown in Figure 3.9a. 
Consistent with our previously published data (Prince et al. , 2004), Tbx2 repressed the p21 
promoter by approximately 2 fold. In the presence of UVC irradiation, however, repression 
of the p21 promoter by Tbx2 was significantly enhanced by approximately 5 fold. TBX2 has 
previously been shown to repress the p14ARF gene (Jacobs et al. , 2000; Lingbeek et al., 2002) 
and therefore the effect of UVC on repression of this gene was next tested. Figure 3.9b shows 
that while Tbx2 repressed the p14ARF promoter by approximately 6 fold, this repression was 
only marginally enhanced by UVC treatment. These results suggest that the enhancement of 
Tbx2 mediated repression by UVC is specific to the p21 promoter. 
The next experiment tested whether the observed repression of p21 by Tbx2 was mediated 
through phosphorylation of Tbx2 by the p38 kinase. A comparison of the ability of WT Tbx2 to 
repress the p21 promoter, to that of the Tbx2 S336A:S623A:S675A and S336E:S623E:S675E 
mutants were thus performed. The results in Figure 3.9c indicate that whereas the WT and 
pseudo-phosphorylated Tbx2 mutant repressed the p21 promoter, abolishing the p38 target sites 
(A mutant) led to an abrogation of this repression . The reason why the pseudo-phosphorylated 
Tbx2 protein behaves as the WT Tbx2 is unclear but it is possible that substitution of serine 
residues with glutamic acid does not mimic exactly the effect of phosphorylation at these sites. 
Another possible explanation may be that WT Tbx2 is phosphorylated by p38 kinase due to the 
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Figure 3.8. Inverse correlation between TBX2 and p21 protein and mRNA levels in response 
to UVC irradiation. (a) p21 protein levels decrease post-UVC treatment. Protein extracts (the 
same used in Fig. 3.3a) from MCF-7 cells at the indicated time points post-UVC irradiation 
(100 J/m2 ) were analysed by 15% SDS-PAGE and western blotting using an antibody to p21. 
The protein extracted from 0 to 30 minutes and 60 to 300 minutes post UVC-treatment were 
analysed on different gels. The results for TBX2, p-p38 and total p38 are the same as shown 
in Fig. 3.3a. (b) p21 mRNA levels are repressed in response to UVC irradiation. Total RNA was 
extracted from MCF-7 cells at the times indicated post-UVC irradiation. Quantitative real-time 
PCR was then performed on reverse transcribed RNA using primers specific to p21 and mRNA 
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Figure 3.9. UVC-induced phosphorylation by p38 kinase enhances the ability of Tbx2 to 
repress p21. (a) UVC irradiation enhances the transcriptional repression of p21 by Tbx2. The 
p21 promoter-luciferase reporter (700 ng) was co-transfected into COS-7 cells either with the 
empty pCMV (200 ng) vector or a Tbx2 (200 ng) expression vector, the cells treated with and 
without UVC (40 J/m2) and luciferase activity determined (left panel). The right panel depicts 
the fold repression which represents the ratio of the luciferase activity generated by the pCMV 
empty vector (without Tbx2) to that obtained in the presence of pCMV-Tbx2. ( *) Indicates 
significant difference from the control (no UVC treatment) at P<0.05. (b) Effect of UVC irradiation 
on the ability of Tbx2 to transcriptionally repress p14ARF. The experiment was repeated under 
the same conditions as described in (a) using 700 ng of the p14ARF promoter-luciferase reporter. 
(c) Mutating the p38 target sites abolishes the ability of Tbx2 to transcriptionally repress the 
p21 promoter. COS-7 cells were transfected as described in (a) with the Tbx2 expression 
vectors, were the identified p38 target sites are either mutated to abolish phosphorylation (A 
mutant) or pseudo-phosphorylated (E mutant) as indicated and luciferase activity determined. 
Western blotting shows equal expression of WT Tbx2 and the Tbx2 mutants in the luciferase 
assays. Error bars represent means± standard deviation. 
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Dr M Galibert). To exclude the possibility that the results obtained may be due to different 
levels of Tbx2 expression for the different constructs used in the transfection assay, protein 
was harvested from parallel dishes and subjected to western blot analyses. The results show 
that equal protein expression was observed for each of the constructs (Fig. 3.9c, lower panel). 
These results suggest that the identified p38 target sites do indeed play a role in regulating the 
transcriptional activity of Tbx2 on the p21 promoter in response to UVC irradiation. 
3.2 The regulation and role of TBX2/Tbx2 in the cell cycle 
Several lines of evidence have implicated a role for TBX2 in the cell cycle (see Chapter 1 ). 
Furthermore, data generated in our laboratory and that of our collaborator, Dr C. Goding (Marie 
Curie Research Institute, UK), have shown that TBX2 binds mitotic chromatin, nucleosomal 
DNA, interacts with the histone H3 tail (Demay et al., 2007) and represses the cyclin-dependent 
kinase inhibitor, p21 (Prince et al., 2004). Based on these data it was speculated that TBX2 
protein expression would be tightly regulated during the cell cycle. A recent study by Bilican 
and Goding (2006) in the 816 mouse melanoma cell line showed that Tbx2 levels are low in 
G1, increase in mid-S-phase and persist at high levels through G2 until finally undergoing 
a dramatic reduction at the onset of mitosis. This change in Tbx2 protein levels does not 
correspond to changes in Tbx2 mRNA levels, suggesting that the protein may be regulated by 
post-translational modifications such as phosphorylation. This possibility was thus explored in 
the present study. 
3.2.1 Cell cycle dependent regulation of the phosphorylation status of Tbx2 
In order to determine whether levels ofTbx2 during the cell cycle are regulated by phosphorylation, 
conditions for synchronising cells in the various phases of the cell cycle had to be established. 
This was accomplished by chemically synchronising 816 cells at specific phases of the cell 
cycle and analysing the cells by flow cytometry. The optimised conditions were as follows: 
cells were synchronised by a double thymidine block to obtain a G1/S population and a S-
phase population was obtained using the same conditions followed by a 2 hr release from 
the thymidine block. G2/M cells were obtained by a thymidine block followed by nocodazole 
treatment, at the end of which mitotic cells were separated by shake-off and the adherent cells 
taken as a G2 population . The cell cycle phase distribution was assessed by measuring DNA 
content using flow cytometry. The data shown in Figure 3.1 Oa confirmed that the cells were 
indeed synchronised in the appropriate phases and these conditions were therefore used for 
future experiments using the B 16 cell line. 
To investigate the phosphorylation status of the endogenous Tbx2 protein at the various phases 
of the cell cycle, synchronised cells were collected and protein extracts were analysed by western 
blotting. The results shown in Figure 3.1 Ob indicate that whereas levels of phosphorylated Tbx2 
are equal in G1 and S-phase cells, they are substantially elevated in G2 cells and dramatically 
reduced in mitosis. These results confirmed that the level of phosphorylated Tbx2 is regulated 
during cell cycle progression . It is worth noting that the intensity of the lower band also increased 


































Figure 3.10. The phosphorylation status of Tbx2 is regulated during the cell cycle with levels 
peaking in G2. (a) Cell cycle distribution of asynchronous (AS) or synchronised cultures (as 
described in section 2.4.2) of 816 cells in specific stages of the cell cycle using flow cytometry. 
(b) The levels of phosphorylated Tbx2 increase during G2 in 816 cells. Protein extracts (62 
J..lg) from either AS or synchronised cells, as described in (a), were analysed by 7.5% SDS-
PAGE and western blotting using an anti-Tbx2 antibody to detect phosphorylated Tbx2. Levels 
of cyclin 81 , cyclin A and total p38 were assessed by loading 20 J..lg of protein and analysis by 
12% SDS-PAGE and western blotting with appropriate antibodies. 
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it may be phosphorylated by a kinase(s) that is active at this phase. Two possible candidates 
were cyclin A/Cdk2 and cyclin 81/Cdk1 which are both required for the events of G2 and M. 
Since cyclin A and 81 are the regulatory subunits of these kinases the protein samples used in 
the above experiment were analysed by western blotting using antibodies to these cyclins. The 
results show that both cyclin A and 81 levels peak in G2. Interestingly, while the cyclin A levels 
are still high in M-phase the cyclin 81 levels drop to undetectable levels at this phase. The 
latter result was unexpected since cyclin 81 is regarded as the most important mitotic cyclin 
but was reproducible in many experiments using mouse 816 melanoma cells. To confirm the 
results obtained above, the experiment was repeated in 81Tbx2 cells, a mouse 3T3 fibroblast 
cell line expressing a low level of exogenous SV5-tagged Tbx2 (Prince et al., 2004). The 
conditions used to synchronise 816 cells in the different phases of the cell cycle were found 
to be effective for the 81 Tbx2 cells (Fig. 3.11 a). Results shown in Figure 3.11 b reveal that 
changes in the levels of Tbx2, cyclin A and 81 are similar to those seen in 816 cells. These 
results suggest that both endogenous and exogenous Tbx2 are regulated similarly during the 
cell cycle and that the regulation of cyclin A and 81 were the same in these two mouse cells. 
In the next set of experiments, the regulation of T8X2, cyclin A and 81 were investigated 
during the various phases of the cell cycle in human cells. Our laboratory has previously 
shown that while T8X2 is expressed in normal lung fibroblasts it is downregulated in several 
transformed human lung fibroblasts including a y-radiated transformed Wl-38 fibroblast cell 
line (CT-1 ). The CT-Tbx2 cell line was established by re-expressing T8X2 into the CT-1 cell 
line (Teng et al., 2007) and these cells were synchronised at specific phases of the cell cycle 
as previously described in section 3.2.1. Protein extracts from these cells were analysed by 
western blotting using the appropriate antibodies. Results are depicted in Figure 3.12. In these 
cells, the level of phosphorylated T8X2 was highest in G2 and hence matched the results 
obtained in the mouse 816 melanoma and 81 Tbx2 fibroblast cells. However, the high level 
of phosphorylated T8X2 persisted in M-phase which contrasted with the results obtained for 
the mouse cells (see Figs. 3.1 Ob and 3.11 b). Interestingly, in these cells the level of the upper 
band was significantly more intense than the lower band, suggesting that the protein is almost 
completed phosphorylated in M-phase. These results suggested that either T8X2/Tbx2 protein 
levels are regulated differently in mouse or human cells or that ectopically expressed T8X2 in 
the CT-Tbx2 cells are regulated differently. To test the latter, the normal Wl-38 lung fibroblast 
cell line that expresses high levels of T8X2 was included in these experiments. Successful 
synchronisation of these cells in mitosis was obtained and the results shown in Figure 3.12b 
indicate that, as seen in CT-Tbx2 cells, high levels of phosphorylated T8X2 are present at M-
phase. As previously observed for the CT-Tbx2 cells the intensity of the upper band was also 
shown to be significantly higher in M-phase. These results suggested that T8X2/Tbx2 may 
be regulated differently in mouse and human cells , however, several mouse and human cell 
lines would have to be analysed in order to clarify this issue. Interestingly, when comparing the 
levels of cyclin A and 81 in the CT-Tbx2 cell line synchronised in the various phases of the cell 
cycle it is evident that they are regulated differently than those in the mouse cell lines examined 
in this study. This discrepancy could not be explained by a lack of specificity or sensitivity of 
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Figure 3.11. The levels of phosphorylated Tbx2 increases during G2 in the B1Tbx2 mouse 
fibroblast cell line. (a) Cell cycle distribution of asynchronous (AS) or synchronised cultures 
(as described in section 2.4.2) of cells in specific stages of the cell cycle using flow cytometry. 
(b) The levels of phosphorylated Tbx2 increase during G2. Protein extracts (80 tJg) from either 
AS or synchronised cells, as described in (a), were analysed by 7.5% SDS-PAGE and western 
blotting using an anti-Tbx2 antibody to detect phosphorylated Tbx2. Levels of cyclin B1, cyclin 
A and total p38 were assessed by loading 50 tJg of protein from these samples by 12% SDS-
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Figure 3.12. High levels of phosphorylated TBX2 persist in M-phase in human lung fibroblast 
cells . {a) The phosphorylation status of TBX2 in CT-Tbx2 cells is regulated in a cell cycle 
dependent manner. Protein extracts (40 IJg) from both AS or synchronised CT-Tbx2 cells (see 
section 2.4.2) were analysed by 7.5% SDS-PAGE and western blotting to detect levels of 
phosphorylated TBX2. Early and late S-phase cells were obtained by a double thymidine block 
followed by release for 2 hr and 4hr, respectively. Levels of cyclin B 1 , cyclin A and total p38 
were detected by loading 18 IJg of protein from these samples by 12% SDS-PAGE and western 
blotting. {b) Phosphorylated TBX2 is present at high levels in normal Wl-38 lung fibroblasts in 
M-phase. Protein extracts (27 IJg) from AS and M-phase cells were analysed by SDS-PAGE 
and western blot analyses as described in (a). 
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regulation of cyclin 81 in mouse and human cells and may indicate that in mouse cells cyclin A 
can substitute for cyclin 81 in mitosis. This observation may be significant and while not further 
explored in this study is discussed in Chapter 4. 
3.2.2 Endogenous TBX2/Tbx2 is phosphorylated by cyclin A/Cdk2 and cyclin 81/ 
Cdk1 
Based on the above results it was hypothesised that TBX2/Tbx2 may be phosphorylated by 
cyclin A/Cdk2 and cyclin 81/Cdk1 which are the kinases active in G2 and M. This possibility 
was particularly attractive as the minimum phosphorylation sites for these kinases are ST/P 
and while there are no TP sites in the TBX2/Tbx2 protein, there are 13 SP motifs. To investigate 
whether Tbx2 is phosphorylated by cyclin A/Cdk2 and/or cyclin 81 /Cdk1 in vivo, 816 cells were 
synchronised in S-phase as previously described in section 3.2.1 and released into G2 in the 
presence of olomoucine, a cyclin B1/Cdk1 and cyclin A/Cdk2 inhibitor (Vesely et al., 1994). 
Protein extracts from these cells were analysed by western blotting using the appropriate 
antibodies and results are shown in Figure 3.13a. As expected, Tbx2 was present at high 
levels in cells synchronised in G2 but in the presence of olomoucine, a significant decrease in 
the levels of the protein was observed. 
The next objective was to determine whether TBX2 levels were regulated by cyclin A/CDK2 
and/or cyclin 81/CDK1 during M-phase in the human CT-Tbx2 cells. To this end, cells were 
synchronised in G2 and released into M-phase in the presence of olomoucine. Figure 3.13b 
shows that in the presence of olomoucine, the levels of phosphorylated TBX2 were significantly 
reduced. These results confirmed that the levels of TBX2/Tbx2 during G2 and M are regulated 
by phosphorylation by cyclin A/Cdk2 and/or cyclin 81/Cdk1. 
3.2.3 Subcellular localisation of TBX2/Tbx2 is regulated during the cell cycle 
Since the subcellular localisation of TBX2 was shown to be regulated by p38 phosphorylation, 
it was possible that the subcellular localisation of TBX2/Tbx2 may also be regulated during 
the cell cycle. This possibility was investigated by synchronising the 816 melanoma and CT-
Tbx2 cells in G1, Sand G2 as described in 3.2.1 and examining the localisation ofTBX2/Tbx2 
by immunofluorescence. Figure 3.14 shows that Tbx2 was located in both the nucleus and 
cytoplasm in 816 melanoma cells synchronised in G1. In cells synchronised inS-phase, Tbx2 
was observed primarily, although not exclusively, in the nucleus and by G2 the protein was 
almost exclusively nuclear. 
Given the differences observed in the regulation of TBX2 in human cells in this study, the 
subcellular localisation of TBX2 was also investigated in CT-Tbx2 cells. Figure 3.15 shows that 
TBX2 is exclusively cytoplasmic in asynchronous and G1 arrested cells. Interestingly, when 
these cells were synchronised in S-phase the protein was either cytoplasmic or nuclear but 
never both. Importantly, almost all cells blocked in G2 exhibited only nuclear staining for TBX2. 
To confirm that the above results were not due to the chemicals used to synchronise the cells, 
immunofluorescence was performed on asynchronous CT-Tbx2 cells using anti-Tbx2 and co-
stained with an antibody specific for Ser1 a-phosphorylated histone H3. Phosphorylation of H3 
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Figure 3.13. , TBX2/Tbx2 is phosphorylated by the cyclin dependent kinases, cyclin A/Cdk2 
and cyclin B1/Cdk1. (a) Tbx2 is phosphorylated in G2 by cyclin A/Cdk2 and/or cyclin B1/Cdk1. 
B 16 cells synchronised in S phase as described in section 2.4.2 were released from the arrest 
in the presence of 80 ~M olomoucine for 2 hr. Protein extracts (70 ~g) were analysed on a 
7.5% SDS-PAGE and subjected to western blotting to detect the phosphorylated form of Tbx2 
using an anti-Tbx2 antibody. Levels of total p38 were assessed by loading 35 ~g of protein 
from these samples by 12% SDS-PAGE and western blotting. (b) TBX2 is phosphorylated in 
vivo by cyclin A/CDK2 and/or cyclin B1/CDK1 during M-phase. CT-Tbx2 cells synchronised in 
M-phase were released from the arrest for 6 hr in the presence of 50 ~M olomoucine. Protein 
extracts (26.5 ~g) were analysed on a 7.5% SDS-PAGE as described in (a) above. As a loading 
control the membrane for the above western blot was stained with Ponceau S. (*) Indicates a 
longer exposure of the blot. 
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TBX2 DAPI MERGE PHASE CONTRAST 
40X 
Figure 3.14. The subcellular localisation of Tbx2 is regulated during the cell cycle in mouse 
B16 cells. Cells synchronised in G1, Sand G2 as described in section 2.4.2 were visualised by 
immunofluorescence at40X magnification using an anti-Tbx2 antibody. All cells were co-stained 
with DAPI, to determine the location of the nuclei. Phase contrast images were photographed 
at the indicated magnification. 
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(a) 
TBX2 DAPI MERGE PHASE CONSTRAST 
40X 
(b) 
DAPI PHOSPHO H3 TBX2 MERGE 
100X 
Figure 3.15. TBX2 localises to the nucleus in human fibroblast cells going through G2. 
(a) CT-Tbx2 cells were synchronised as described in Fig. 3.12a. Cells were visualised by 
immunofluorescence at 40X magnification using an antibody to Tbx2. Phase contrast images 
of the CT-Tbx2 were captured at the indicated magnification. (b) TBX2 co-localises with 
phospho-Histone 3 (H3) in the nuclei of G2 cells. Asynchronous CT-Tbx2 cells were stained 
with TBX2 and phospho-H3 which generates a specific punctate pattern of staining during G2. 
The fluorescent images depicted were captured at 1 OOX magnification. The merged image 
is an overlay of the TBX2, DAPI and phospho-H3 stain. All cells were stained with DAPI , to 








Figure 3.16. Phosphorylation by cyclin A/CDK2 and/or cyclin B1/CDK1 regulates the nuclear 
localisation of TBX2 at G2. Asynchronous CT-Tbx2 cells were treated for 4 hr with 50 IJM 
olomoucine and analysed by immunofluorescence using anti-Tbx2 and Ser10-phosphorylated 
H3 antibodies. All cells were stained with DAPI. The panels represent images captured at 
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Figure 3.17. Cyclin A/Cdk2 and cyclin B1/Cdk1 directly bind Tbx2 in vivo. (a) Interaction of 
Tbx2 and cyclin A/Cdk2. 816 cell extracts synchronised in G2 and enriched with cyclin A were 
incubated with either GST-Tbx2 or GST only, which served as a negative control. Unbound 
cell extracts were included as a positive control. To show that an equal amount of protein was 
used in each lane the membrane was stained with Ponceau S (lower panel). Tbx2-bound 
proteins were resolved by 12% SDS-PAGE and binding to the cyclin was detected using an 
antibody specific to cyclin A. (b) Tbx2 binds cyclin B1/Cdk1. 816 cell extracts was prepared 
and analysed as described in (a). Binding to cyclin 81 was detected using the appropriate 
antibody. A non-specific band, which cross-reacts with the cyclin 81 antibody, is indicated with 
an asterisk(* ). The position of Tbx2 and GST are indicated on the membranes. 
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To map the region of Tbx2 that interacts with cyclin A, a series of [35S]methionine-labeled 
Tbx2 deletion proteins were generated using an in vitro transcription/translation system. 
The [35S]methionine-labeled Tbx2 proteins were individually incubated with either bacterially 
produced GST-cyclin A or GST only, which served as a negative control. The input (20% of the 
reaction) and cyclin A-bound proteins were analysed by 12% SDS-PAGE. Protein interaction 
with the labelled Tbx2 proteins was visualised by autoradiography and the results are shown 
in Figure 3.18. As expected, cyclin A bound full length Tbx2, and while the N-terminal Tbx2 
fragments (amino acids 1-202 and 114-376) were able to bind cyclin A, no binding was observed 
for the C-terminal fragment (amino acids 371-711 ). Interestingly, the minimum region that cyclin 
A bound within the N-terminal Tbx2 fragment was amino acids 147-295 which contains the 
DNA binding domain (T-box). 
Previous work generated by Dr S. Prince in our laboratory has already established that cyclin 
81 binds Tbx2 within its DNA binding domain and hence these experiments were not repeated. 
It would appear that both cyclin A and cyclin 81 bind Tbx2 within the same region, which 
interestingly does not contain any of the reported cyclin recognition motifs (KXL, RXL) and thus 
suggests a novel interaction between Tbx2 and the cyclins. 
3.2.6 Tbx2 is phosphorylated by cyclin A/CDK2 and cyclin B1/CDK1 in vitro 
Having established that cyclin A and cyclin B 1 bind to Tbx2, the next objective was to determine 
whether Tbx2 was phosphorylated by the cyclin A/CDK2 and cyclin B1/CDK1 complexes. As 
mentioned earlier, SP motifs are the minimum potential target sites for phosphorylation by the 
CDKs and all 13 SP sites present in the Tbx2 protein had previously been mutated to alanine 
by site-directed mutagenesis. WT Tbx2 and the 13 mutated proteins were expressed as GST-
tagged fusion proteins which were used as substrates for in vitro cyclin A/CDK2 kinase assays. 
These assays utilise [y-32P]ATP and thus the results were visualised by autoradiography. As 
in the p38 kinase assays, the GST-Tbx2 fusion proteins were expressed as either N-terminal 
(1-371) or C-terminal (371-711) proteins (Fig. 3.19a). 
The results in Figure 3.19b (i) indicate that whereas the WT GST-Tbx2 N-terminal protein (1-
371) was phosphorylated by cyclin A/CDK2, the C-terminal (371-711) protein was not. There 
are three SP motifs within the N-terminal protein that may be CDK2 target sites. However, 
whereas S342A had no effect on phosphorylation of the N-terminal portion of Tbx2, the S 192A 
and S336A mutations both reduced phosphorylation by the cyclin A/CDK2 complex. To confirm 
that these two sites were cyclin A/CDK2 target sites, a S192A:S336A double mutant was 
generated, expressed as a GST-tagged fusion protein and included as a substrate together 
with the proteins tested above in a kinase assay. Figure 3.19b (ii) shows that whereas the 
single mutations S 192A and S336A reduced phosphorylation of the N-terminus of Tbx2, when 
they were both mutated phosphorylation was severely reduced to almost background levels. 
GST alone was used as a negative control. The lower panels in Figure 3.19b show the gels 
stained with Coomassie Blue indicating that equivalent amounts of GST-fusion proteins were 
used in these experiments. The bar graphs, which depict densitometric values of radioactive 
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Figure 3.18. Cyclin A binds Tbx2 within the T-box. Schematic diagram of the [35S]methionine-
labeled WT and Tbx2 deletion proteins generated in vitro using the TNT quick coupled 
transcription-translation system (left panel , not to scale). The indicated [35S]methionine-labeled 
Tbx2 deletion proteins were used to map the minimal interaction domain that cyclin A requires 
to bind Tbx2 (right panel). 20% of the reaction was retained as input and the remainder of the 
reaction was incubated with an equal amount of GST or GST-Cyclin A. Tbx2 in both the input 
and GST-containing lanes were detected by autoradiography. The striped box indicates the 
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Cyclin B1 /Cdk1 mutant 
Figure 3.19. Tbx2 is phosphorylated by cyclin A/Cdk2 and cyclin B1/Cdk1 at specific serine 
residues in vitro and in vivo. (a) Schematic representation of the N-terminal (1-371) and C-
terminal (371-711) Tbx2 proteins used as substrates in CDK2 kinase assays. (b) Mapping the 
Cyclin A/CDK2 kinase target sites within Tbx2. In vitro kinase assays were performed using 
purified GST-Tbx2 fusion proteins as substrates in the presence of the recombinant activated 
cyclin A/CDK2 kinase and [y-32P]ATP. Kinase assays using the indicated Tbx2 proteins are 
shown in the upper panel after 12% SDS-PAGE and autoradiography. The lower panels show 
the same gels stained with Coomassie Blue indicating that equivalent amounts of protein 
were used in each assay. The bar graphs shows densitometric values of radioactive levels 
measured for each construct in the kinase assay. (c) Mutating the cyclin A/Cdk2 and cyclin 81/ 
Cdk1 kinase sites affects the phosphorylation of Tbx2 in vivo. SV5 epitope-tagged Tbx2 or the 
cyclin A/Cdk2 (S 192A:S336A) and the cyclin B 1 /Cdk1 (S336A:S342A) mutant were transiently 
transfected in COS-7 cells and an equal amount of protein from each sample was separated 
by 7.5% SDS-PAGE and western blotting to analyse the phosphorylation status of Tbx2 using 
an anti-SV5 antibody. p-Tbx2 is phosphorylated Tbx2. 
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levels measured for each substrate, confirmed the visual results of the kinase assays. These 
results show that Tbx2 is phosphorylated specifically by the cyclin NCDK2 kinase at 8192 and 
8336 in vitro. 
Previous work done by Dr 8. Prince using the same substrates as above in an in vitro kinase 
assay with cyclin 81/CDK1 showed that Tbx2 is phosphorylated by this kinase complex at 
serine residues 336 and 342. Taken together, the results show while cyclin NCDK2 and cyclin 
81/CDK1 target a common site (8336) within the Tbx2 protein, they each have an additional 
distinct target site. 
3.2.7 Tbx2 is phosphorylated at the cyclin A/Cdk2 and cyclin B1/Cdk2 target sites 
in vivo 
To determine whether the cyclin NCdk2 and cyclin 81/Cdk1 target sites are sites for 
phosphorylation in vivo, Tbx2 mutants were generated in which the cyclin NCdk2 or cyclin 81/ 
Cd k 1 target sites were mutated to alanine within the fu 11-length Tbx2 protein (Tbx2 8 192A: 8336A 
and Tbx2 8336A:8342A, respectively). C08-7 cells were transfected with vectors expressing 
either 8V5-tagged WT Tbx2 or 8V5-tagged mutant proteins and the phosphorylation status 
of Tbx2 analysed by western blotting. Figure 3.19c shows that unlike the two bands seen for 
WT Tbx2, both the cyclin NCdk2 (8192A:8336A) and cyclin 81/Cdk1 (8336A:8342A) mutant 
proteins showed up as a single band. These results suggest that the identified cyclin NCdk2 
and cyclin 81/Cdk1 target sites are indeed phosphorylated in vivo. 
3.2.8 Functional significance of Tbx2 phosphorylation by cyclin A/Cdk2 and cyclin 
B1/Cdk1 
To determine the functional consequences of Tbx2 phosphorylation by the cyclin NCdk2 and 
cyclin 81/Cdk1 kinases, the next objective was to investigate the effect of phosphorylation by 
these kinases on Tbx2 (a) protein stability and (b) ability to repress transcription. 
3.2.8.1 Phosphorylation by cyclin B1/Cdk1 but not cyclin A/Cdk2 increases Tbx2 
protein stability 
To investigate the effect of cyclin NCdk2 and/or cyclin 81/Cdk1 phosphorylation on the stability 
of the Tbx2 protein, NIH 3T3 cells were transiently transfected with either WT Tbx2 or Tbx2 
mutant proteins in which cyclin NCdk2 (8192:8336) or cyclin 81/Cdk1 (8336:8342) target 
sites were mutated to either alanine (A), to abolish phosphorylation or to glutamic acid (E), to 
mimic phosphorylation. The transfected cells were treated with cycloheximide over a period of 
6 hr at the indicated times and protein analysed by western blot analyses using a 8V5 antibody 
(Fig. 3.20). In order to accurately quantify total levels of Tbx2 protein, in this experiment cell 
lysates were separated by a 10% 808-PAGE and hence Tbx2 is detected as a single band. 
The results obtained for WT Tbx2 and the cyclin NCdk2 mutants, (8192A:8336A and 8192E: 
8336E), are shown in Figure 3.20a. Whereas the levels of the WT Tbx2 protein remained 
almost unchanged over the period of cycloheximide treatment, the levels of the Tbx2 8 192A: 
8336A mutant protein decreased after 1 hr and continued to decline with increasing duration of 
cycloheximide treatment. These results suggest that abolishing phosphorylation at 8192 and 
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Figure 3.20. Pseudo-phosphorylation at the cyclin B1/Cdk1 but not cyclin A/Cdk2 target 
sites increases Tbx2 protein stability. (a) NIH 3T3 cells, transiently transfected with vectors 
expressing SV5 epitope-tagged WT Tbx2 and the cyclin A/Cdk2 Tbx2 mutants were incubated 
48 hr post-transfection with 30 IJg/ml CHX for the indicated times. To accurately detect total 
levels of the Tbx2 protein as a single band, an equal amount of protein from each sample was 
analysed by 10% SDS-PAGE and western blotting with anti-SV5 antibodies. The bar graph 
compares the intensity of the Tbx2 protein normalised to the loading control. (b) Western blot 
analyses of protein from NIH 3T3 cells transiently transfected with vectors expressing SV5 
epitope-tagged WT Tbx2, the Tbx2 S336A:S342A mutant or the Tbx2 S336E:S342E mutant, 
and treated with 30 IJg/ml CHX as described above. Proteins were analysed as described in 
(a) above. 
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S192E:S336E mutant protein behaved exactly the same as the Tbx2 S192A:S336A mutant 
protein, which was puzzling and a possible explanation for this is provided at the end of this 
section. The densitometric graphs in the lower panels compare the intensity of the Tbx2 protein 
normalised to the loading control. 
Figure 3.20b shows results obtained for WT Tbx2 and the cyclin B1/Cdk1 mutants, (S336A: 
S342A) and (S336E:S342E). As seen in previous experiments, the levels of WT Tbx2 remained 
reasonably stable during the period of cycloheximide treatment and a similar result was 
obtained for the pseudo-phosphorylated Tbx2 mutant (S336E:S342E). In contrast, the Tbx2 
S336A:S342A mutant exhibited significantly reduced protein levels after 3 hours and very low 
levels at 6 hours of cycloheximide treatment. These results indicate that phosphorylation of 
Tbx2 by cyclin B1/Cdk1 at serine residues 336 and 342 enhances Tbx2 protein stability. 
It is important to point out at this stage that this study shows that serine 336 in Tbx2 is a target 
for the p38 kinase, cyclin A/Cdk2 and cyclin B1/Cdk1. Since the Tbx2 mutants that mimic 
phosphorylation by p38 and cyclin B1/Cdk1 are more stable than their A mutant counterparts, 
the question arises as to whether the effect seen for the mutant that mimics phosphorylation 
by cyclin A/Cdk2 is a consequence of mutating 8192 located in the DNA binding domain. It 
is possible that substitution of serine residues with glutamic acid does not mimic exactly the 
effect of phosphorylation at these sites and that even a small difference between glutamic acid 
and a phosphate group(s) may have deleterious effects on a protein depending on the position 
of the substitution, with S 192 being such an example. 
3.2.8.2 Phosphorylation by cyclin B1/Cdk1 enhances the ability of Tbx2 to repress 
the p21 promoter 
Tbx2 may be playing a critical role in the regulation of the cell cycle, particularly at the G2 
and/or M phase. One possible mechanism of how Tbx2 may contribute to the maintenance 
of cell cycle progression is postulated to be through its ability to repress transcription of the 
cyclin-dependent kinase inhibitor, p21. As previously discussed (see Chapter 1 ), p21 is critical 
for mediating a cell cycle arrest through its association with appropriate cyclin/Cdk complexes 
in response to cellular stress. It was therefore hypothesised, given the importance of p21 in the 
regulation of key cellular processes such as the cell cycle, senescence and cancer that a key 
experiment would be to test the ability of the cyclin A/Cdk2 and cyclin B1/Cdk1 Tbx2 mutants 
to repress the transcriptional activity of p21. To this end, COS-7 cells were co-transfected with 
either WT Tbx2 or the Tbx2 mutants in which the cyclin A/Cdk2 and cyclin B 1/Cdk1 target sites 
had been mutated to alanine (A) or to glutamic acid (E) together with a p21 promoter-luciferase 
reporter. The results, in which each construct was tested in duplicate, are shown in Figure 
3.21 a and 3.21 b. 
Figure 3.21 a depicts the result of three different experiments, which shows the effect of the 
cyclin A/Cdk2 mutants on the p21 promoter. While co-transfection with a WT Tbx2 expression 
vector consistently resulted in an approximately 3 fold repression of the p21 promoter, the 
effect of the cyclin A/Cdk2 mutants was however not reproducible. Both the Tbx2 (S192A: 
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Figure 3.21. Pseudo-phosphorylation at the cyclin B1/Cdk1 target sites enhances the ability 
of Tbx2 to repress p21. The p21 promoter-luciferase reporter (700 ng) was co-transfected 
into COS-7 cells either with the empty pCMV (200 ng) vector or with the (a) Tbx2 expression 
vectors in which the cyclin A/Cdk2 sites had either been abolished (S192A:S336A) or 
pseudo-phosphorylated (S192E:S336E) and (b) the Tbx2 expression vectors in which the 
cyclin B1/Cdk1 sites had either been abolished (S336A:S342A) or pseudo-phosphorylated 
(S336E:S342E) and luciferase acitivity determined. Error bars represent means ± standard 
deviation. 
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S336A) and (S192E:S336E) mutants was shown to either behave similarly to WT Tbx2 or 
exhibit increased repression on the p21 promoter. As previously discussed in section 3.2.8.1, 
a possible explanation for these inconsistent results could be that substitution of S 192 located 
in the DNA binding domain of Tbx2 with either A or E may disrupt the structure of the Tbx2 
protein. The results from these experiments are thus inconclusive. 
In contrast, in these experiments the Tbx2 (S336E:S342E) mutant that mimics phosphorylation 
by cyclin B1/Cdk1 consistently exhibited increased repression on the p21 promoter (Fig. 
3.21 b). These results were also shown to be reproducible using CAT reporter assays (data not 
shown). The results suggest that phosphorylation of Tbx2 by cyclin B1/Cdk1 kinase enhances 
its transcriptional repression on the p21 promoter. 
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CHAPTER 4: DISCUSSION 
Members of the T-box family play important roles in a wide variety of developmental processes 
and two family members, TBX2 and TBX3, have been shown to contribute to the growth and 
survival of several cancers. Importantly, TBX2 and TBX3 were identified as immortalising . 
genes capable of bypassing replicative senescence through their ability to repress p19fl.RF and 
p21 (Jacobs et al., 2000; Brummelkamp et al., 2002; Lingbeek et al., 2002; Prince et al., 2004). 
' Despite their important roles in a number of biological processes, very little is known about the 
biochemical pathways that regulate the levels and transcriptional activity ofT-box factors. In 
view of the detrimental consequences resulting from altered levels ofT-box proteins, as seen 
in both developmental disorders and in certain cancers, the need to identify such pathways 
is important. This study has therefore focused on identifying signal transduction pathways 
and kinases that regulate the levels and activity of TBX2. To this end, it was firstly important. 
to establish whether TBX2 is phosphorylated in vivo. Protein extracts from the MCF-7 breast 
cancer cell line were therefore treated with and without shrimp alkaline phosphatase and 
results from western blot analyses showed that the endogenous TBX2 protein is expressed as 
two bands, with the top band representing the phosphorylated protein. Furthermore, the TBX2 
protein sequence was shown to have 13 SP motifs that are potential target sites for several 
kinases and this study shows that some of them are phosphorylated by the stress-induced p38 
kinase, and the G2/M cyclin A/Cdk2 and cyclin B 1/Cdk1. 
TBX2 is phosphorylated by the p38 MAP kinase in response to stress induced by UVC 
irradiation 
Cellular senescence can be triggered by alterations of telomeres as well as in response to a 
variety of stresses, such as DNA damage caused by irradiation and cytotoxic drugs (reviewed 
in Roninson, 2003). The p38 signalling pathway plays an important role in diverse cellular 
responses such as cell cycle progression, differentiation, apoptosis (reviewed in Zarubin and 
Han, 2005) and has also been identified as a senescence signalling pathway which is activated 
in response to both telomere dependent and independent senescence (lwasa et al., 2003; Haq 
et al., 2002; Wang et al., 2002). In response to DNA-damaging agents, such as UV irradiation, 
the p38 MAP kinase signal transduction cascade is initiated to inhibit cell cycle progression 
. and to activate DNA-repair processes, thereby maintaining the integrity of the genome. The 
present study provides several lines of evidence that TBX2 is phosphorylated by the p38 MAP 
kinase in response to stress induced by UVC irradiation. 
Firstly, phosphorylation ofTBX2 was shown to increase with increasing doses of UVC irradiation 
and this was reversed in the presence of the p38 inhibitor, 88203580. Secondly, using in vitro 
kinase assays, Tbx2 was shown to be phosphorylated at serine residues 336, 623 and 675 
and these sites were confirmed to be phosphorylated in vivo. Furthermore, in response to UVC 
treatment the phosphorylation status of the Tbx2 mutant (S336A:S623A:S675A) remained 
unchanged, confirming that the sites identified were the only sites targeted for phosphorylation 
by p38. 
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Importantly, phosphorylation by the p38 MAP kinase was shown to have a significant effect on 
TBX2 function. For example, the Tbx2 protein appears less stable when the three p38 serine 
target sites were mutated to block phosphorylation. This effect of p38 phosphorylation on the 
stability of its substrates has previously been reported for the G1 proteins, p53 and cyclin 
D1. Whereas p38 phosphorylation of p53 led to increased protein stability, phosphorylation 
of cyclin D1 by this kinase resulted in ubiquitin-dependent degradation and consequently a 
G1 arrest (Casanovas et al., 2000; Bulavin et al., 1999; Keller et al., 1999). To confirm that 
phosphorylation by p38 at serine residues 336, 623 and 675 protects Tbx2 from degradation 
it would be important to examine the stability of endogenous TBX2 in response to UV in the 
presence of 88203580 using pulse-chase labeling. 
Moreover, TBX2 mRNA levels also increased in response to UVC irradiation but the 
mechanism(s) for this still needs to be elucidated. It is tempting to speculate that the ubiquitous 
bHLH-LZ transcription factor USF-1 may be involved. This is possible because both TBX2 and 
USF-1 are expressed in melanocytes and USF-1 has been shown to play an important role in 
mediating the tanning response, which protects skin from UV-induced DNA damage (Carreira 
et al., 1998; Galibert et al., 2001 ). During the tanning response, phosphorylation of USF-1 by 
the p38 MAP kinase results in an increase in USF-1 binding to conserved E and M box motifs 
and consequently activation of genes that encode enzymes involved in the melanin synthesis 
pathway (Galibert et al., 2001 ). The Tbx2 promoter has been shown to possess an E box 
(Carreira et al., 2000) and it would be interesting to see if it is capable of responding to USF-
1, particularly in response to UV irradiation. To test this theory, future work should determine 
whether USF-1 is able to bind the TBX2 promoter in vitro and in vivo using electromobility shift 
and chromatin immunoprecipitation assays respectively. In addition, the effect of USF-1 on the 
promoter activity of TBX2 could be assessed by co-transfecting cells with a USF-1 expression 
construct and the TBX2-LUC reporter construct, UV irradiating the cells, and then measuring 
luciferase activity. It is anticipated that in response to UV irradiation the stress-responsive 
USF-1 transcription factor will bind and transciptionally activate the expression of TBX2. 
TBX2 was shown to localise to both the cytoplasm and nucleus but upon UVC irradiation, 
phosphorylation of TBX2 by the p38 MAP kinase led to the predominant nuclear localisation 
of the protein. This result would suggest that the activity of TBX2 is controlled, in part, by the 
regulation of its subcellular localisation. This is not the first study to suggest the importance of 
the subcellular distribution ofT-box factors in regulating their functional activity. For example, 
in C. elegans, tbx2 is involved in olfactory adaptation and the protein is mostly localised to the 
cytoplasm of olfactory and many pharyngeal neurons, suggesting that nuclear translocation 
may regulate its activity (Miyahara et al., 2004). Certain T-box family members have also been 
found to possess nuclear localisation signals (NLS), which may explain the shuttling of these 
proteins into the nucleus. In patients suffering from DiGeorge syndrome, the deletion of the 
NLS in Tbx1 has been shown to prevent the mutant protein from localising to the nucleus, 
resulting in haploinsufficiency (Stoller and Epstein, 2005). Furthermore, deletion of the Tbx3 
NLS, RREKRK, at amino acids 292-297 results in mislocalisation of the protein to either 
perinuclear or cytoplasmic sites (Carlson et a f., 2001 ). 
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Given the high degree of homology between TBX2 and TBX3, the human and mouse TBX2 
protein sequences were screened for the TBX3 NLS. Not surprisingly, the TBX3 NLS was found 
to be conserved at exactly the same position in the TBX2 protein. It will therefore be interesting 
to investigate whether the identified NLS plays a role in shuttling TBX2 into the nucleus and 
whether phosphorylation of the protein by the p38 MAP kinase can regulate this process. A 
key experiment would thus be to delete the identified TBX2 NLS and in the presence and 
absence of UVC irradiation monitor the translocation of TBX2 to the nucleus using fluorescent 
microscopy. There is, however, another possible mechanism by which phosphorylation by p38-
mediated phosphorylation can regulate the translocation of TBX2 into the nucleus. It is well 
established that the p38 kinase does not possess a NLS or nuclear export signal (NES) and 
that the shuttling of p38 to the nucleus occurs via specific docking interactions with NES- and 
NLS containing proteins, such as p38 activators, substrates or scaffold proteins (reviewed 
in Cyert, 2001 ). Therefore in response to UVC irradiation, it is also likely that active p38, in 
complex with NLS containing proteins, binds and phosphorylates TBX2 in the cytoplasm and 
enables its translocation to the nucleus as part of this complex. 
The effect of UVC-induced p38 phosphorylation on TBX2 protein levels and nuclear localisation 
would suggest a role for this transcription factor in the stress signalling pathway. There has 
been a lot of controversy in the literature regarding the role and regulation of the Tbx2 target, 
p21, in response to UV-induced DNA damage. While certain studies suggest that p21 plays 
a positive role in the DNA damage repair pathway, other studies have suggested that its 
degradation is required for this process. The present study shows that in response to UVC 
irradiation, p21 protein levels are rapidly increased but decrease equally rapidly post-UVC 
treatment. This is consistent with recent reports that in response to DNA damage, p21 levels 
initially increase in order to establish a senescence-like growth arrest by binding to appropriate 
cyclin/Cdk complexes and by inhibiting the activity of proliferating cell nuclear antigen (PCNA) 
(Fig. 4.1 a). Subsequently however, p21 has been shown to be downregulated which is thought 
to be required for the activation of PCNA which is a key component of the nucleotide excision 
repair (NER) pathway (Pan et al., 1995; Cooper et al., 1999; Bendjennat et al., 2003). One 
mechanism by which p21 is downregulated in response to UV-induced DNA damage has 
been shown to involve ubiquitin-dependent proteolysis (Bendjennat et al., 2003). The present 
study however shows that p21 mRNA levels also decrease immediately in response to UVC 
irradiation with levels remaining low for up to 60 min post-treatment. This finding is consistent 
with a study by Wang et al (1999) which demonstrated that both p21 protein and mRNA levels 
are downregulated post-UV irradiation of MCF-7 cells. The observed decrease in p21 mRNA 
levels post-UVC treatment correlated with an increase in TBX2 protein levels, which raised the 
possibility that TBX2 may be required to inhibit p21 in the UV-stress signalling pathway. Indeed, 
in response to UVC irradiation TBX2 was shown to be a much stronger repressor of the p21 
promoter and mutating the three p38 serine target sites within TBX2 abrogated its ability to 
repress p21. These results suggest that TBX2 may be required to inhibit p21 mRNA levels in 
the UV-induced DNA damage pathway which contributes to the downregulation of p21 protein 
levels as depicted in Figure 4.1. To test this model, a key experiment would be to determine 
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Figure 4.1. Possible model for the mechanism by which TBX2 represses p21 in response to stress-induced DNA damage. (a) Established model for 
the role of p21 in response to cellular stress. (b) Suggested model for the role of TBX2 in the DNA damage pathway. 
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the effect of silencing TBX2 by siRNA on p21 levels in the presence of UVC irradiation. This 
would involve transfecting TBX2 siRNA into MCF-7 cells, exposing the cells to UVC irradiation 
and then using real-time PCR to analyse the expression of p21. It is anticipated, that if TBX2 is 
responsible for keeping the p21 gene repressed that p21 mRNA levels should increase. 
It is important to note that since these studies were performed in a breast cancer cell line 
that overexpresses TBX2 it is possible that the effects seen on p21 may be due to TBX2 
inappropriately inhibiting p21 in response to DNA damage. This would result in cells cycling 
with damaged DNA which could lead to genomic instability, which is a hallmark of cancer. It 
would therefore be important to repeat the above experiments in a breast epithelial cell line 
expressing normal levels of endogenous TBX2. 
The cell cycle regulated TBX2 is a target for cyclin A/Cdk2 and cyclin B1/Cdk1 
Several lines of evidence have implicated a role for TBX2 in the cell cycle. For example, it 
was shown to act as an anti-senescence factor capable of repressing the Cdki's, p1f}ARF and 
p21 (Jacobs et al., 2000; Lingbeek et al., 2002; Prince et al., 2004). Furthermore, a role for 
TBX2/Tbx2 at G2 and/or early M has been suggested by studies that have shown that its 
protein levels are tightly regulated during the cell cycle with levels peaking at G2 (Bilican and 
Goding, 2006) and ectopic expression of TBX2 leads to several mitotic defects and genomic 
instability (Davis et al., 2007; Demay et al., 2007). This study shows that the increase in TBX2 
levels previously seen during G2 is due to phosphorylation. The same result was obtained in 
the mouse B1Tbx2 fibroblast cell line, which stably expresses exogenous Tbx2. An interesting 
observation was that in contrast to the mouse cell lines used in this study, phosphorylated 
TBX2 persists at high levels in human cells synchronised in M-phase. These results allude to 
the possibility that TBX2 may be regulated differently in cell lines of human and mouse origin 
and hence that it may have different roles in the cell cycle in these two species. While these 
results are intriguing, many more cell lines of human and mouse origin would have to be 
analysed to test this possibility. Moreover, it is important to point out that the regulation of TBX2 
levels during the cell cycle must be due to post-translational modifications because exogenous 
TBX2 protein levels in CT-Tbx2 and B1Tbx2 are driven by constitutively active viral promoters 
and yet behave similar to the human and mouse endogenous TBX2 protein respectively. 
It was hypothesised that the increased levels in phosphorylation of TBX2 at G2/M imply that 
it is a substrate for the cyclinA/Cdk2 and/or cyclin B1/Cdk1 complexes, which phosphorylate 
proteins required for the events of G2 and M. The present study provides evidence to suggest 
that this is the case. Firstly, when 816 mouse melanoma and CT-Tbx2 human fibroblast cells 
were treated with olomoucine, a Cdk1 and Cdk2 inhibitor, a dramatic decrease in Tbx2/TBX2 
protein levels at G2 and M in mouse and human, respectively was observed. These results 
suggest that the increased levels of TBX2/Tbx2 at G2 and Mare due to phosphorylation by 
Cdk1 and/or Cdk2. Secondly, TBX2 was shown to be exclusively nuclear in G2 cells and this 
localisation appears to be regulated by phosphorylation by Cdk1 and/or Cdk2, since in the 
presence of olomoucine the protein does not enter the nucleus. Other studies have also shown 
that phosphorylation by the cyclin/Cdk complexes regulates the subcellular localisation of its 
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target substrates. For example, phosphorylation of CDC6, a key regulator in the initiation of 
DNA replication, by cyclin A/CDK2 induces the translocation of the protein from the nucleus to 
the cytoplasm to prevent re-replication of the DNA (Peterson et al., 1999). The results presented 
in the present study show for the first time that phosphorylation of T8X2/Tbx2 by cyclin A/Cdk2 
and/or cyclin 81/Cdk1 regulates the levels and subcellular localisation of the protein in a cell 
cycle dependent manner. 
The above results raised the question as to whetherT8X2/Tbx2 is phosphorylated and regulated 
by both cyclin A/Cdk2 and cyclin 81/Cdk1 or by only one of the two. It was postulated that 
since cyclin A/Cdk2 and cyclin 81/Cdk1 are both active at G2/M it was unlikely that they would 
target the same substrate. Interestingly, not only was Tbx2 shown to bind both cyclin A and 
cyclin 81 but it was also shown to be phosphorylated by both cyclin/Cdk complexes. However, 
while the two kinases share a common target site in Tbx2, they each also have a second 
distinct target site. The identified cyclin A/Cdk2 and cyclin 81/Cdk1 sites were also shown to be 
phosphorylated in vivo as mutating these serine residues abolished phosphorylation of Tbx2. 
Although limited, there is some evidence in the literature to suggest that both Cdk1 and Cdk2 
in association with the appropriate cyclin can indeed bind and differentially phosphorylate a 
common substrate. For example, an investigation by Santaguida and Nepveu, (2005) show 
that the homeodomain protein, CDP/Cux, is differentially phosphorylated by cyclin A/Cdk2 
and cyclin A/Cdk1. While phosphorylation by cyclin A/Cdk2 allows CDP/Cux DNA-binding 
during S phase, phosphorylation by cyclin A/Cdk1 was shown to inhibit the DNA-binding and 
transcriptional activity of CDP/Cux in G2. Although it is generally accepted that Cdk1 and 
Cdk2 recognise a common consensus sequence, it has been shown that any variation from 
this sequence can affect the specificity and kinase activity of the Cdk towards its potential 
substrates (Holmes and Solomon, 1996). It is therefore possible that variation in the sites 
adjacent to the SP motifs within T8X2 may lead to its differential phosphorylation by cyclin 
A/Cdk2 and cyclin 81/Cdk1, which may have different effects on the function of the protein. 
Cyclin A and cyclin 81 were both shown to bind T8X2 within its DNA-binding domain, which 
suggests that these two cyclins may compete for binding to T8X2. Interestingly, results 
previously generated in our laboratory showed that unlike the S192A mutant, the Tbx2 S192E 
mutant which mimics phosphorylation by cyclin A/Cdk2 was unable to bind cyclin 81/Cdk1 in 
vivo. The present study explored the functional significance of T8X2 phosphorylation by cyclin 
A/Cdk2 and cyclin 81/Cdk1. While the results obtained for cyclin A/Cdk2 were inconclusive, 
the positive effect of cyclin 81/Cdk1 on T8X2 protein stability and transcriptional activity was 
reproducibly demonstrated. It is therefore possible that phosphorylation of T8X2 by cyclin AI 
Cdk2 serves to prevent inappropriate stabilisation and transcriptional activity of the T8X2 protein 
due to premature binding and phosphorylation by cyclin 81/Cdk1. This theory is supported by 
data generated by our UK collaborators who showed that when cyclin A was knocked down 
by siRNA in human cells, T8X2 levels increased. It is also worth noting that in the mouse 
cells tested in the present study, the downregulation of Tbx2 in M-phase corresponds with the 
absence of cyclin 81. This further supports the notion that phosphorylation by cyclin 81/Cdk1 
is responsible for stabilising Tbx2. To resolve this issue it would be important to knock-down 
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cyclin 81 and determine the consequence on T8X21evels. In the event that T8X21evels remain 
high, both cyclin A and 81 may need to be knocked down together to determine whether they 
are both capable of regulating T8X2 levels and can substitute for one another. Furthermore, 
given the limitations of the use of olomoucine in distinguishing between phosphorylation by 
Cdk1 and Cdk2, it would be important to test the effect of an inhibitor specific for either Cdk2 
or Cdk1 on T8X2 phosphorylation during the cell cycle. 
The results in this study which show that pseudo-phosphorylation of Tbx2 by cyclin 81/Cdk1 
enhances the ability of Tbx2 to repress p21 raised the question of the potential significance 
of this effect. It was speculated that T8X2 may function to repress p21 in order to allow cells 
to progress into mitosis. While p21 is generally regarded as a negative regulator of the cell 
cycle, it was recently shown to play a positive role in G2/M progression. At G2/M, a transiently 
hyperphosphorylated form of p21 binds cyclin 81 to promote the assembly and activation of 
the cyclin 81/Cdk1 complex (Dash and EI-Deiry, 2005). However, immediately after activating 
cyclin 81/Cdk1, the hyperphosphorylated form of p21 was shown to be rapidly downregulated 
to promote progression into mitosis. The mechanism for this was, in part, recently elucidated 
by Amador et al. (2007) who showed it involves the ubiquitin ligase APCfCCdc2o. Results from 
the present study would suggest that in addition to p21 protein degradation, phosphorylation 
of T8X2 by cyclin 81/Cdk1 may also downregulate p21 mRNA levels. 
One of the most unexpected results to emerge during this study was the difference in the 
expression of cyclin A and 81 during the various phases of the cell cycle in the mouse and 
human cell lines tested. While it is widely accepted that cyclin 81 in association with Cdk1 
plays a critical role in the early phases of mitosis, cyclin 81 was undetectable in the mouse, 
but not human cells, synchronised in M-phase. In the mouse cells high levels of cyclin Awere 
however observed in M-phase suggesting that cyclin A may substitute for cyclin 81 to complex 
with Cdk1. This is not unlikely since both cyclin A and cyclin 81 have been shown to be capable 
of associating with Cdk1 and Cdk2 (reviewed in Kaldis and Aleem, 2005; L'ltalien et al., 
2006). The absence of cyclin 81 in M-phase in mouse cells cannot be explained by a lack of 
specificity of the cyclin 81 antibody because the antibody recognises cyclin 81 in all the other 
phases of the cell cycle. This effect on the downregulation of cyclin 81 has previously been 
observed in polyploid megakaryocytes, which fail to undergo complete mitosis (Zhang et al., 
1996, 1998). The ubiquitin-dependent degradation of cyclin 81 was postulated to contribute 
to the genesis of polyploidy by abrogating mitosis in these cells (Zhang et al., 1998). While 
816 mouse melanoma cells are polyploidy tumour cells (8aroja et al., 1996), early passage 
81Tbx2 cells did not display features of polyploidy (our unpublished data). However, based on 
previous published data from our laboratory that show that ectopic expression of T8X2 leads to 
polyploidy (Davis et al., 2007), it is possible that with increasing passage in culture these cells 
may indeed become polyploid and hence metaphase spreads would need to be performed on 
later passage cells. 
In conclusion, the present study has identified the stress-responsive p38 MAP kinase and 
the cell cycle regulatory complexes, cyclin A/Cdk2 and cyclin 81/Cdk1 as novel regulators of 
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TBX2. The results generated for the p38 kinase demonstrate that TBX2 may be required to 
inhibit p21 mRNA levels in order to enable DNA damage repair in response to UV irradiation. 
The results showing that phosphorylation of TBX2 by cyclin A/Cdk2 and/or cyclin B1/Cdk1 
regulates the stability and subcellular localisation of the protein provides additional support for 
a role for TBX2 in G2 and/or early M. 
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APPENDIX 
2.2 Site-directed mutagenesis of the mouse Tbx2 eDNA 
NYZ+ Broth 
10 g NZ amine 
5 g yeast extract 
5 g NaCI 
Adjust to pH 7.5 using NaOH 
Autoclave 
Add the following supplements prior to use: 
12.5 ml 1M MgCI2 
12.5 mi1M MgS04 
1 0 ml of 2 M filter-sterilised glucose solution or 
20 ml 20% (w/v) glucose 
Filter sterilize 
2.3.2 Mycoplasma test 
Mounting fluid 
1.1 M Citric acid 
1.2 M Na2HP04.2H20 
1 00% glycerol 
Adjust to pH 5.5 
Aliquot and store at 2-8°C 
2.4.2 Cell cycle synchronisation and Flow cytometry 
Phosphate Buffered Saline (PBS) 
8 g NaCI 
1.45 g Na2HP04.12H20 
0.2 g KCI 
0.2 g KH2P04 
Adjust to pH 6.9, make up to 1 litre and autoclave 
Propidium iodide stain 
0.1% Triton X-100 
0.002 M MgCI2 
0.1 M NaCI 
0.01 M PIPES 
0.01 mg/ml propidium iodide 
Cover with foil and store at -20°C 
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2.4.4 Cycloheximide treatment 
2X SDS loading buffer 
125 mM Tris-HCI (pH 6.8) 
4%SDS 
2% glycerol 
2-4 mg bromophenol blue 
10% 13-mercapto-ethanol 
Aliquot and store at 4°C 
2.4.5 Phosphatase treatment 
5X SDS loading buffer 
0.25 M Tris-HCI (pH 6.8) 
1%SDS 
10% glycerol 
2-4 mg bromophenol blue 
Aliquot and store at RT 
2.9 Western blot analyses 
RIPA buffer 
150 mM NaCI 
1% Triton X-100 
0.1% SDS 
10 mM Tris-HCI (pH 7.5) 
1% deoxycholate 
Store at 4°C 
Supplement with 1 mg/ml aprotinin, 1 mg/ml Pepstatin A and 2 mM phenylmethanesulfonyl 
fluoride protease inhibitors (Sigma, USA) just before use. 
Blocking solution 
5% non-fat dry milk dissolved in 0.1% Tween-20 in PBS 
2.9 Bacterial expression and purification of glutathionine S-tranferase (GST) fusion proteins 
PBSTi Buffer 
1% Triton X-100 
1X PBS 
Supplemented with 4 complete proteinase inhibitor tablets (Roche, Switzerland) 
Store at -20°C 
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2.10 In vitro kinase assay 
Kinase buffer 
20 mM MOPS (pH 7 .2) 
25 mM 13-glycerophosphate 
5 mM EGTA 
1 mM sodium orthovanadate 
1 mM dithiothreitol 
Store at -20°C 
[y-32P]ATP (Amersham Biosciences, USA} 
10 JJM Ci diluted with 91JI of 400 JJM unlabelled ATP, 75 mM MgCI2 
2.11 In vitro transcribed translated binding assays 
In vitro transcribed translation reaction 
1 IJ9 Tplink DNA 
40 JJI TNT T7 Quick master mix 
3 IJI [35S] methionine (1.175Ci/mmol at 10 j.JCi/JJI) 
2 j.JI 25X EDT A-free proteinase inhibitor tablets (Roche, Switzerland) 
Make up to a final volume of 50 JJI with nuclease-free H
2
0 
2.12 GST-pulldown assays 
RIPA 150 mM NaCI buffer 
0.05 M Tris-HCI (pH 8) 
0.15 M NaCI 
0.1% NP-40 
0.1% sodium deoxycholate 
0.1% SDS 
5mM EDTA 
1 mM OTT 
10 mM NaF 
0.01 mM sodium orthovanadate 
2 complete proteinase inhibitor tablets (Roche, Switzerland) 
Store at -20°C 
2.13 Quantitative reverse transcription PCR (qRT-PCR) 
t,.t,.Ct method 
Formula ratio = (Etarget)CPiarget(control·sample)/(Eref)CPref(control·sample); E: real-time PCR efficiency, CP: 
crossing point (Pfaffl, 2001 ). 
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